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Feline leukemia virus, strain KT, is a retrovirus that causes a fatal erythroid aplasia. 
The fatal loss of erythrocytes is due to the interaction of this virus with the BFU-E 
stage of feline erythropoietic development. This virus is comparable to the human 
HTLV retrovirus. Through the development of a computer mathematical model, we 
demonstrate the disease process and show that infection of the BFU-E leads to a 
characteristic fatal erythroid aplasia in cats. 
 
Fetal feline lymphohematopoietic stem cells, before a certain point in gestation, 
lack genotypically unique class I major histocompatibility cell-surface antigens 
(FLA). The elucidation of a gestational time point when FLA appear on the surface of 
cells within the fetal liver will provide knowledge of when hematopoietic stem cells 
may be at maximal utility for gene therapy of feline hematopoietic disease, 
  
specifically FIV. Here we show that this time point occurs around day 40 in fetal 
feline gestation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 MATHEMATICAL AND MOLECULAR STUDIES OF                                        
FELINE ERYTHRO- AND LYMPHOPOIESIS 
 
 
                                                                      by 
 
                                                              Bren S Ewen 
 
 
 
                       Thesis submitted to the Faculty of the Graduate School of the  
                          University of Maryland, College Park in partial fulfillment 
                                            of the requirements for the degree of 
                                                          Master of Science 
                                                                    2005 
 
 
 
 
 
 
 
Advisory Committee: 
 
             Professor Wenxia Song, Chair 
             Professor Sam Joseph 
             Professor Carol M. Pontzer 
              
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          ©Copyright by 
 
                                                            Bren S Ewen 
 
                                                                  2005
  
 DEDICATION 
 
 
 To Ann Ewen, my dear mother, whose life taught me that I could weather any 
storm and survive any trial; and whose dedication to life helped me grasp hold of my 
dreams and make every moment of every day count.  
 
To Pat Beacham, without whose help this research would not have been possible. I 
can never repay the debt I owe. 
 
To Sadie Ann Ewen, whom saved my life. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ii 
 
 ACKNOWLEDGEMENTS 
 
 
 
I wish to acknowledge the work of Dr. E. A. Hoover, whose FeLV data was given 
to me for use in the construction of the mathematical model and made available for 
my use in publications of this research. 
 
I wish to acknowledge the assistance of Dr. Rick Kohn in determining the proper 
modeling software and mathematical analysis equations for construction and testing 
the mathematical model. 
 
I wish to acknowledge Dr. Ayalew Mergia and Dr. Milton Hernandez for assisting 
me to obtain a grant to support the work upon which this thesis is based. 
 
I wish to acknowledge the assistance of Dr. Suresh Poosala for his help with the 
Tissue Array and Immunohistochemistry Procedures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iii 
 
  
Table of Contents 
 
Dedication.....................................................................................................................ii 
Acknowledgements......................................................................................................iii 
List of Data Tables....….....……………………………………………………..........vi 
List of Figures. ……………………………………......…………………………......vii 
List of Abbreviations…......…………………………………….…………........…….ix 
 
Chapter I: Computer Modeling of Normal and Feline Leukemia Virus-Infected Feline                               
                 Erythropoiesis...............................................................................................1 
                 Overview and Significance……………......………………………....….....1   
                        FeLV-KT-Induced Erythroid Aplasia……………………....…………2                               
                 Mathematical Modeling of Normal Feline Erythropoiesis…...….……..….3     
                        Specific Aims……………………....…………………...…….……….3     
                        Rationale................................................................................................3                               
                        Method…………........………………………………………………..3                                
                        Results…....………………………………..………………………….9                                
                 Mathematical Modeling of FeLV-KT-infected Feline Erythropoiesis.......12                               
                    Specific Aims……………………....…………………..………….....12                               
                    Rationale…....................……...........…………...……………………12                               
                    Method………..…...........………………..……………...…………...13                               
                    Results……........……………………..………………………………21                               
                  Model Evaluation….......………..……………………..…………………41    
                       
Chapter II: The Appearance of the Feline Major Histocompatibility Complex on Fetal 
Liver Cells During Feline Gestation...........................................……………..……...44 
                   FLA …………..…….......…………………..…………………......…….44 
                   Hematopoietic Stem Cells and Stem Cell Therapy….….………............46 
                   Immunophenotypes of Mammalian HSC…….......................……..........50 
                   Clinical Utility of Stem Cells………………………..………......………52 
                   The Fetal Feline Liver…...………………………..…………….......…...57 
                   Determination of the Appearance of FLA upon the Surface of Fetal Liver  
                   Cells..........................................................................................................59 
                       Specific Aims…………….………………..……………………....…59 
                       Rationale…...………………......…………………………......….…...59 
                       Methods…...………………………………...……………....….…….60 
                       Results…..........…………………………………………..….......…...61 
 
Chapter III: Feline Studies and the Relation to Human Studies…...…………….......66 
                       Human Immunodeficiency Virus (HIV).......………………..………..66 
                       Graft versus Host Disease and Transplant Therapy……..…………...68 
                    Future Studies….... …………….………………………………………71 
                       Expanding the Mathematical Model……………………….………....71 
                       Expanding the Antibody Studies…………………..........……….…...71 
 iv 
 
 References....................................................................................................................74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 v 
 
 LIST OF DATA TABLES 
 
 
1. TABLE 1. Comparison of Cats Displaying Acute, Protracted and Latent FeLV-
AA................................................................................................................................22 
 
2. TABLE 2. Comparison of the effects of traditional antiviral treatments versus stem 
cell gene therapy…..............…………………………………………………………54 
 
 vi 
 
 LIST OF FIGURES 
 
Figure Number                                                                                                       Page                               
 
1. FIGURE 1. High Level Mathematical Model Map Layer ………….……………..6 
 
2. FIGURE 2. Mathematical Model of Normal Feline Erythropoiesis........................11 
 
3. FIGURE 3. Determination of FOCMA antibody titers in cells of FeLV-KT-
infected cats................................................................................................................ 23 
 
4. FIGURE 4. Determination of FeLV antibody titers in FeLV-KT-infected cats.... 24 
 
5. FIGURE 5. Determination of the erythrocyte packed cell volume (VPRC or Hct) in 
FeLV-KT-infected cats............................................................................................... 25 
 
6. FIGURE 6. Comparison of the volume of packed red cells from cats displaying 
FeLV-KT infection and non-infected control littermates........................................... 26 
 
7. FIGURE 7. The comparison of red blood cell counts and reticulocyte counts in cats 
displaying acute FeLV-KT infection ................................................................…......27 
 
8. FIGURE 8. Differential cell count (Diff) showing the Granulocyte/Monocyte 
counts of white blood cells in acute FeLV-KT-infected cats compared to littermate 
control cats..................................................................................................................28 
 
9. FIGURE 9. Results of lymphocyte cell counts from the differential cell counts of 
FeLV-KT inoculated cats compared to control littermate cats...................................29 
 
10. FIGURE 10. The determination of erythroid progenitor cell growth in acute 
FeLV-KT-infected cats, compared to VPRC..............................................................31 
 
11. FIGURE 11. Bone marrow histology of FeLV-KT-infected cats compared to 
control littermate cats..................................................................................................33 
 
12. FIGURE 12. Comparison of body weights of FeLV-KT-infected cats with non-
infected, control littermates.........................................................................................34 
 
13. FIGURE 13. The Mathematical Model of FeLV-KT Infected Feline 
Erythropoiesis.............................................................................................................36 
 
14. FIGURE 14. Mathematical Modeling Graph of FeLV-KT infected BFU-E…....38 
 
15. FIGURE 15. Graph of the decline of Hct in cats inoculated with FeLV-KT over 
time ……………….................................................................................…...……….39 
 
 vii 
 
 16. FIGURE 16. Results of FeLV-infection upon the Hct from the Mathematical 
Model..........................................................................................................................40 
 
17. FIGURE 17. Comparison of the Human MHC to the Feline FLA……………...45 
 
18. FIGURE 18. Positive results of immunohistochemical staining with anti-MHC 
Class I on a 58 day old feline fetal liver .....................................................................62 
  
19. FIGURE 19. Positive results of immunhistochemical staining with anti-MHC 
Class I on a 58 day old fetal feline liver..........................................................……....63 
 
20. FIGURE 20. Negative results of immunhostochemical staining with anti-MHC 
Class I on cells within a feline fetal liver sample........................................................64 
 
21. FIGURE 21. Negative results of immunohistochemical staining of a 32 day old 
feline fetal liver with anti-MHC Class 1.....................................................................65 
                                          
 viii 
 
 LIST OF ABBREVIATIONS USED 
  
1. AA – Aplastic Anemia 
2. BFU-E – Burst Forming Unit-Erythroid  
3. BMT- Bone Marrow Transplant 
4. CFU-E – Colony Forming Unit-Erythroid 
5. Diff – Differential Cell Count 
6. DPI – Days Post Inoculation 
7. EA – Erythroid Aplasia 
8. FeLV – Feline Leukemia Virus 
9. FeLV-AA – Feline Leukemia Virus induced Aplastic Anemia 
10. FeLV-EA – Feline Leukemia Virus induced Erythroid Aplasia (also called FeLV-   
      AA) 
11. FeLV-KT – Feline Leukemia Virus, strain KT 
12. FHSC – Fetal Hematopoietic Stem Cells 
13. FIV – Feline Immunodeficiency Virus 
14. FLA – Feline Major Histocompatibility Antigens 
15. FOCMA – Feline Oncovirus-Associated Cell Membrane Antigen 
16. FFU – Focus Forming Units 
17. GCSF – Granulocyte-colony Stimulating Factor 
18. GVHD – Graft-versus-host-disease 
19. Hct. – Hematocrit or VPRC  
20. HIV – Human Immunodeficiency Virus 
21. HSC(s) – Hematopoietic Stem Cell(s) 
 ix 
 
 22. HSCT – Hematopoietic Stem Cell Transplant 
23. Kg - Kilogram 
24. mg – milligram 
25. ml – milliliter 
26. MHC – Major Histocompatibility antigens 
27. MPA – Methyl Prednisolone Acetate 
28. ORFs – Open reading frames 
 
29. RBC(s) – Red Blood Cell(s) 
30. RMSPE – Root Mean Square Prediction Error  
31. SPF – Specific Pathogen Free 
32. VPRC – Volume of Packed Red Blood Cells 
 
 
 x 
 
 CHAPTER I: 
Computer Modeling of Normal and Feline Leukemia Virus –Infected Feline 
Erythropoiesis 
Overview and Significance 
The Kawakami-Theilen strain of feline leukemia virus (FeLV-KT or FeLV-C)) is an 
exogenous anemia-inducing retrovirus. FeLV is the most important infectious disease 
agent producing fatal illness in domestic cats today. Additionally, its relation to the 
human HTLV virus makes it an attractive model for study of the pathogenesis of 
diseases related to infection with the virus.  This knowledge will hopefully allow 
more insights into preventions and treatments for both FeLV infection in cats and 
HTLV infection in humans. 
 
FeLV is excreted in saliva and tears, the urine and the feces of infected cats. 
Prolonged, extensive cat-to-cat contact is required for efficient spread because the 
virus is rapidly inactivated by warmth and drying. There are three main types of 
feline leukemia virus: FeLV-A, FeLV-B, and FeLV-C (FeLV-KT). FeLV-positive 
cats can be infected with one, two, or all three types:  
1. FeLV-A occurs in all FeLV-infected cats and causes severe                        
immunosuppression.  
2. FeLV-B occurs in about 50% of all FeLV-infected cats and causes more 
neoplastic disease than cats infected only with FeLV-A.  
3. FeLV-C, or FeLV-KT, occurs in about 1% of FeLV-infected cats and causes 
severe anemia.  
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 After the initial infection, the virus replicates in the tonsils and pharyngeal lymph 
nodes. It then spreads via the bloodstream to other parts of the body, especially the 
lymph nodes, bone marrow, and intestinal tissue, where it continues to replicate. 
Viremia usually presents 2 to 4 weeks after the initial infection.  
 
FeLV is one of the most devastating feline diseases worldwide. In the United States, 
FeLV infects about 2% to 3% of all cats. Cats ill from other acute or chronic 
disorders are four times more likely than healthy cats to be infected with FeLV. 
Researchers estimate that about 50% of cats with severe bacterial infections, and 75% 
of cats with toxoplasmosis also have FeLV infections.  
 
FeLV-KT-Induced Erythroid Aplasia 
Experimentally induced FeLV-erythroid aplasia is a fatal normocytic and 
normochromic anemia associated with bone marrow hypoplasia, lymphopenia, 
leukopenia and, less consistently, with myeloschlerosis.4-6 Of the recognized strains 
of FeLV, only FeLV-KT isolates have been shown to induce FeLV-erythroid 
aplasia.5-8 The FeLV virus targets the Burst Forming Unit-Erythroid (BFU-E) cells in 
the erythropoietic developmental pathway, blocking the production of fully mature 
red blood cells. It has been speculated that FeLV-KT might arise de novo in cats with 
FeLV-A viremia, perhaps as a recombinant of FeLV-A and endogenous cellular DNA 
sequences.9-10 Although the association of marrow aplasia with FeLV-KT is known, 
the pathogenesis of the virus has remained unclear.  
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Mathematical Modeling of Normal Feline Erythropoiesis 
Specific Aims 
To begin to study the pathogenesis of FeLV-KT using a mathematical model, it is 
important to first construct a working model of normal erythropoiesis, to verify that 
such a model can predict the outcomes of real-time feline erythropoiesis.  
 
Rationale 
In order to create a realistic and useful model for the examination of FeLV-KT 
infection and subsequent red cell aplasia, the model must first be able to mimic 
normal feline erythropoiesis. Because we hope to show that the infection by FeLV-
KT causes a characteristic loss of red cells, it is important that any model, developed 
adequately and accurately, demonstrate the normal development of these cells. The 
influential factors include the number of changes, mitoses and different time values 
these cells undergo to produce a steady state of 1x109 RBCs. 
 
Materials and Methods 
Mathematical Modeling 
Development of a precise model of normal erythropoiesis will provide the 
opportunity for the perturbation of this system and the targeted placement of FeLV-
KT at the level of the fifth mitotic stage of BFU-E development. The successful 
development of this model will support the real system data, demonstrating a 
characteristic slope produced by the loss of Hct.  
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Stella 5.1.1, Research Version, created by High Performance Systems, Inc., was the 
software utilized for the construction of both normal and FeLV-KT-infected feline 
erythropoiesis. This software has many benefits over other types on the market, in 
that it is amenable to the incorporation of data and real system outputs from bench 
experiments and automatically assigns differential equations to the expressions 
created within the model layer. Before the discussion of the mathematical model can 
begin, the elements used in the creation of this prototype must first be defined in 
order for the reader to have a clear understanding of the construction of our 
representation of erythropoiesis.  
 
There are three map layers found within the model: 1.The High-Level Map Layer 
2.The Model Layer 3. The Equation Layer.  
The High Level Map layer displays the essential actors or the overall picture found 
within the model layer (Fig. 1). Here we not only show the big picture but the 
interaction of each major player with the other. The three aspects that we have 
determined to constitute the predominate parts of erythropoiesis are: 
- feline hematopoietic stem cells 
- the erythropoietic development pathway   
- circulating mature red blood cells.                                                                                                           
 
The model layer is where the true workings are found. This section is composed of 
the major cell compartments found in our model. Within each compartment, the 
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 principle part of modeling occurs. It is necessary to define the tools used in the 
formation of our erythropoietic representation.  
The first tool used in the development of our model was the stock. The stock can 
carry out 4 distinct mathematical functions, depending on the device chosen. Two 
different types were used; a reservoir, which allowed a certain number of items, in 
our case these are cells, to remain within the stock. The second stock device used was 
the conveyor. A conveyor, representing the cell compartment, allowed items to flow 
into it, stay a certain amount of time, carry out certain functions, i.e. divide or mature, 
and then leave after that end time  point is reached. 
Reservoir Conveyor
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 providing switches for special effects, in this case the virus of interest, Feline 
Leukemia Virus-KT. 
 
 
The second tool applied to the model was the flow. The purpose of the flow is to fill 
and to drain accumulations. In the model of erythropoiesis, these flows carry the cells 
from one compartment, or stock, to another. The unfilled arrowhead on the flow pipe 
indicates the direction of flow. The “cloud” at the beginning of the flow merely 
represents the fact that the items are not moving from any out side source, or are 
originating and controlled by the stock into which they flow. 
Flow  
A third tool employed was the converter, which will be discussed in the next 
experimental section dealing with the creation of FeLV-KT-infected erythropoiesis. 
 
The last major tool, important to the Model Layer development, is the connector. The 
connector was used to connect model elements, such that the element from where the 
connector originated controlled or directed the movement of the cells in the item to 
which the connector pointed. In the example below, the red arrows are the connectors. 
These arrows signify that the differentiation fraction and the hematopoietic stem cells 
control erythropoietic differentiation. When a model element is opened, by double 
clicking using a computer mouse, a dialog box opens allowing the modeler to write 
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 an equation. In the example shown the equation would be: 
Hematopoietic_Stem_Cells*Differentiation_Fraction 
The actual equation is 8 (Hematopoietic Stem Cells) multiplied by 1/8 
(Differentiation Fraction) so that only one stem cell undergoes erythropoietic 
differentiation at any one time under the conditions of normal erythropoietic 
development. 
Hematopoietic Stem Cells
Erythropoietic Differentiation
Differentiation fraction
 
When constructing the FeLV-infected computer model, we “transplanted” 8 
hematopoietic stem cells into the system, allowing one HSC to give rise to a total of 
109 mature red cells or packed red cells. The number of stem cells was determined as 
it has been demonstrated in mice, cats, dogs and primates, that only 8 stem cells are 
required to repopulate the lymphohematopoietic architecture.18 The pathway was 
modeled in log scale to give a biologically correct analysis of the synthetic system. 
Both the BFU-E and CFU-E cell compartments contained 5 distinct mitoses. The 
cell(s) multiplied by a factor of 1.584893192, within each mitosis, to simulate actual 
biological events, as suggested by Wichmann and Loeffler.11  
 
We will explore the discussion of FeLV viral control within the model in the next 
section. Briefly, certain expressions enabled a toggle switch, which was connected 
from the High Level Map layer to a converter representing FeLV on the model layer, 
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 to control the presence and absence of FeLV, subsequently controlling feline stem 
cells and BFU-E cells and further impacting all cell compartments along the 
erythropoietic differentiation pathway. The virus either infected the BFU-E cells 
(toggle switch returned a value of 1 and was turned on; virus was present), stopping 
further division and causing cell death or was absent from the cells (toggle switch 
returned a value of 0 and was turned off). The loss of BFU-E cells and VPRCs, as 
well as the shift of HSCs to the erythropoietic pathway, were then analyzed through 
the software’s graphical and animation utilities. 
 
One of the major benefits of using the Stella software package was the automatic 
assignment of differential equations to each part of the diagram. In calculus parlance, 
the software used flows to represent time derivatives; stocks were the integrals (or 
accumulations) of flows over time; converters contained the micro-logic of flows.  
                                                                      
Results 
As a first step, we designed a model to imitate normal, feline erythropoietic 
development (Figure 2). It is known that between the BFU-E stage and the 
reticulocyte stage, there is a 5-fold increase in the cell numbers. There are 5 distinct 
mitoses that take place within the BFU-E compartment. The average time for a cell to 
under go all 5 is 24 hours. Additionally, it takes an average of 8 hours for a cell 
entering the CFU-E stage of development to undergo all 5 CFU-E distinct mitoses.11-
12 It is also known that complete feline erythropoietic development requires an 
average of 70 days.13 These facts were incorporated into our model setup to ensure 
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 biological authenticity. The end result of this model was that one HSC gave rise to 
109 red blood cells and the model maintained a steady state. 
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 Feline Fetal Stem Cells
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 Figure 2. The Mathematical Model of Normal Feline Erythropoiesis. On the 
model layer, the elements described above were used in the construction of normal 
feline erythropoiesis. 
 
Mathematical Modeling of FeLV-KT-infected Feline Erythropoiesis 
Specific Aims 
It is believed that FeLV-KT targets the fifth mitotic stage of development of the BFU-
E cells, due to the presence of a particular protein on the cell surface at this stage. It is 
the aim to introduce the virus at this stage in the model, with everything else 
resembling normal feline erythropoiesis, in order to display a characteristic decline in 
red blood cells within the model, which is also seen in experimentally infected cats. 
The model was constructed for the comparison to real-system outputs, in the hopes 
that it could be expanded to predict other erythro- and lymphopoietic disruptions and 
outcomes.  
 
Rationale 
Once EA is induced by the abatement of precursor cells in the 5th mitotic BFU-E 
stage by the targeted attack of FeLV-KT, hematocrit (Hct) decreases in a 
characteristic manner. To show that this effect is reproducible and is due to the 
targeted infection of a particular cell population, the normal erythropoietic pathway 
will be disrupted by the introduction of the virus into the model at this point. The 
amount of viral particles represented will be the average number of focus forming 
units (ffu) inoculated into experimental animals. 
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 Method 
Bench top research was conducted by Dr. E. A. Hoover at Colorado State University. 
The real system outputs from the following experiments were used as a comparison to 
modeling outputs and a basis for the construction of the model.  
Cats 
Cats used were derived exclusively from a nonseasonal SPF breeding colony 
originated in the Department of Veterinary Pathobiology, The Ohio Sate University 
and re-established in the Department of Veterinary Pathology, Colorado State 
University. These cats were free of FeLV exposure. Fifty-six juvenile SPF cats (mean 
age 72.2 +/- 1.6 days) were inoculated with the Kawakami Theilen strain of FeLV 
(FeLV-KT). Twenty-seven littermates or age-matched SPF cats served as controls. 
Virus Inoculation and Sampling 
FeLV-KT was employed as an infectious spleen homogenate derived from serial 
passage of virulent virus in SPF cats.4, 13-14 Juvenile cats were inoculated 
intraperitoneally with between 1.3 x 103 and 2.3 x 105 focus forming units (ffu) of 
FeLV-KT (mean ffu, 7.0 x 104 +/- 1.0 x 104). Both FeLV-inoculated and control cats 
received 10 mg/kg of methyl prednisolone acetate (MPA) intramuscularly at the time 
of and 7 days post inoculation (DPI). At 7 day intervals after the original inoculation, 
both control and inoculated cats were anesthetized with ketamine hydrochloride and 
2.5 ml blood was collected for the following determinations: total and differential cell 
count, reticulocyte count, erythrocyte packed cell volume, FeLV p27 antigen in 
leukocyte, and antibody against the feline oncornavirus-associated cell membrane 
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 antigen (FOCMA) and antibody against FeLV. Heparinized femoral or humoral bone 
marrow aspirates (1ml) from 6 inoculated and 6 control cats were collected for in 
vitro assay of CFU-E/BFU-E and bone marrow cytology. 
 
Cats were euthanized when the VPRC was less than 5%. Post mortem examination 
was performed on all cats and duplicate tissues were fixed in phosphate-buffered 
formalin and absolute methanol for histopathology and for identification of FeLV p27 
antigen distribution respectively.  
Infectious FeLV Quantitation 
Sera and homogenates of spleen and bone marrow from FeLV infected and control 
cats were examined for infective FeLV with the clone 81 focus induction assay 
described by Fischinger et al.15  
Latent FeLV Detection 
Latent FeLV in bone marrow cells was reactivated by culture of 5 x 107 bone marrow 
mononuclear cells in 25 cm3 flasks for 7 days.16 Supernatants were assayed for 
infectious virus as described above. 
In Vitro CFU-E/BFU-E Determination 
Marrow mononuclear cells were separated by colloidal silica buoyant density 
centrifugation (density 1.070 g/ml) and cultured as described by Abkowitz et al.17 
Erythropoietic, purified from the plasma of anemic sheep (Connaught, Willowdale, 
Ontario, Canada) was added to the cultures (0.5 units/ml); no conditioned media were 
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 used. Colonies were enumerated in duplicate cultures by inverted plate phase contrast 
microscopy; CFU-E were counted on day 5 and BFU-E on day 11 of culture. 
 
Mathematical Modeling 
By interrupting the model of normal erythropoiesis at the 5th mitotic BFU-E stage 
through the introduction of an element representing FeLV-KT, a characteristic loss of 
Hct should develop and lead to a similar slope of the graph shown by real system 
outputs.  
 
It has been proposed that end stage aplastic anemia occurs as a secondary effect to the 
decline of the erythroid compartment.18 By using Stella 5.1.1 to create a model of 
FeLV-KT-infected erythropoiesis, we demonstrate how simulated cytopathicity, at 
the level of the BFU-E, displays the same kinetics of the anemia observed in cats with 
experimentally induced FeLV-erythroid aplasia. The simulated decline in BFU-E 
creates an impediment to further maturation and differentiation of committed stem 
cells entering this pathway. Cessation of red cell production and an increase of stem 
cells committed to the erythropoietic pathway in an attempt to relieve the loss of red 
cells are two results of this impediment. As red cells are lost and no further cells 
become available, through viral targeting of the BFU-E, the body’s demand increases 
and a shift occurs away from the production of other blood cell types. This shift from 
the production of other hematopoietic cell lineages is an attempt by the HSC to fulfill 
the body’s erythropoietic demand. The greater the loss of red cells the higher the 
number of HSC committed to the erythropoietic differentiation pathway.  
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Ablation of BFU-E proliferation antecedent to all other hematologic changes 
indicates that the BFU-E progenitor cell is the most important target cell for the 
cytopathic effect of anemogenic FeLV-KT. Our findings confirm those of Onions and 
Testa who have reported that FeLV-KT, or FeLV subgroup C, suppresses BFU-E in 
experimentally infected newborn kittens.19 Using virulent in vivo selected, highly 
anemogenic FeLV isolates, BFU-E abatement is virtually concurrent with retroviral 
infection of hematopoietic cells. When this data was used in construction of a 
mathematical model, it supported the experimental results of the effect of FeLV-KT 
upon the BFU-E, demonstrating that subsequent marrow failure is a secondary 
outcome to the loss of BFU-E progenitors 
  
Data from original experiments, carried out by Dr. E.A. Hoover and Dr. Peter Gasper 
at The Ohio State University and Colorado State University, were entered into the 
software program Excel. Cats used to obtain this data were derived exclusively from a 
nonseasonal SPF breeding colony originated in the Department of Veterinary 
Pathobiology, The Ohio State University and re-established in the Department of 
Pathology, Colorado State University in 1981.20 These cats were free of FeLV 
exposure. Fifty-six juvenile SPF cats (mean age 72.2 +/- 1.6 days) were inoculated 
with FeLV-KT. Thirty of these cats exhibited FeLV-associated EA. Twenty-seven 
littermate or age-matched SPF cats served as controls. FeLV-KT was employed as an 
infectious spleen homogenate derived from serial passage of virulent virus in SPF 
cats.20 Juvenile cats were inoculated intraperitoneally with between 1.3 x 103 and 2.3 
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 x 105 focus forming units (ffu) of FeLV-KT. Both FeLV-inoculated and control cats 
received 1-mg/Kg of methylprednisolone acetate (MPA) intramuscularly at the time 
of and 7 days post inoculation (DPI). At 7 day intervals after inoculation, both control 
and inoculation cats were anesthetized with ketamine hydrochloride and 2.5 ml blood 
was collected for the following determinations: total and differential cell counts, 
reticulocyte count, erythrocyte packed cell volume (VPRC or Hct), FeLV-p27 antigen 
in leukocytes, antibody against the feline oncornavirus-associated cell membrane 
antigen (FOCMA) and antibody against FeLV. FOCMA is a protein expressed on 
certain feline cancer cells, especially lymphoma and leukemia cells. The presence of 
FOCMA antibodies in healthy cats often indicates a latent infection with FeLV. 
FeLV-p27 is a structural component of the FeLV inner viral core. This protein can be 
found in great abundance in infected blood cells and in soluble form in plasma and 
serum of viremic cats.  
 
Heparinized femoral or humoral bone marrow aspirates (1 ml) from 6 inoculated and 
6 control cats were collected for in vitro assay of Colony Forming Unit-Erythroid 
(CFU-E)/BFU-E and bone marrow cytology. Cats were euthanized when the VPRC 
was less than 5%. Post mortem examination was performed on all cats and duplicate 
sets of tissues were fixed in phosphate-buffered formalin and absolute methanol for 
histopathology and for identification of FeLV p27 antigen distribution, respectively.  
Data obtained and entered were from felines displaying FeLV infection with aplastic 
anemia, those latently infected and those used as controls. The information entered 
included results of the cell counts of BFU-E, CFU-E, reticulocytes, VPRC, or Hct, 
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 lymphocytes, granulocytes, monocytes, the age of the cats, the weights of cats, 
antigen-antibody studies (FeLV and FOCMA) spanning a 140 day time period. The 
primary cell counts used in construction of the FeLV-KT-infected model were the 
BFU-E.  
 
As mentioned above, in constructing the erythropoietic mathematical models the third 
tool employed was the converter. The converter appeared as a stand-alone circle on 
the Model Layer. This instrument served a utilitarian role in the software. It held 
values for constants, defined external inputs to the model, calculated algebraic 
relationships and served as the repository for graphical functions. In general, it 
converted inputs into outputs. Within the structure of our model of erythropoiesis, it 
served several different functions. We put it into play to control division time, death, 
division, differentiation and maturation factors, total cell numbers and, most 
importantly, it represented the feline leukemia virus. 
Converter  
In our model, we “transplanted” 8 HSC into the system. This number was chosen as it 
has been shown that only 8 HSC are required to give rise to the complete 
hematopoietic architecture after total body irradiation (TBI).18 The pathway was 
modeled in log scale analog. Both the BFU-E and the CFU-E cell compartments 
contained 5 distinct mitoses. The virus was introduced using a converter entitled 
“Introduction of FeLV”. The mean focus forming units (ffu) of viral particles was 
written within this converter and we employed the average amount of the real system 
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 inoculation, 7 x 104 ffu. Additionally, FeLV was created within the model to mimic 
normal viral reproduction and death. The loss of BFU-E was initiated at the fifth 
stage of division, using a flow to represent BFU-E loss. This loss only occurred when 
a toggle switch, to which the virus was connected, was turned on. The software 
contained these “switches” in order to permit model builders to create on/off behavior 
for variables or sectors in a model. When attached to a converter, a switch would 
return a 1 when on and a 0 when off. An equation was written within the BFU-E loss 
flow regulator allowing the infection to occur at this fifth stage of division when the 
toggle was “on” through the interaction of a connector from the “Introduction of 
FeLV” to the BFU-E loss flow. The reasons for setting the loss at the fifth mitotic 
stage of BFU-E development are two-fold: (1) we suspected that certain cell surface 
proteins, with which the virus interacts, were either not accessible or not expressed 
prior to reaching this stage of development. Since our initial hypothesis it has been 
shown that the FeLV-C receptor, named FELVCR or gp70, does not appear on the 
surface of BFU-E cells until the fifth division stage.(2) Recent evidence by Abkowitz, 
et al., has shown that the virus interacts and disrupts the BFU-E at this 5th division 
stage or, possibly, between BFU-E division stage 5 and CFU-E division stage 1.21 
Other connectors were used to initiate the effects of the viral infection at the level of 
the reticulocytes, marrow erythrocytes and circulating erythrocytes. The equations 
used to simulate virus interaction and subsequent effects are as follows: 
(1) Within the BFU-E loss flow the equation stated “IF Introduction_of_FeLV=1 
THEN BFUe Death ELSE 0”. As may be obvious, this instructed the flow to lose 
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 BFU-E cells only upon introduction of the virus, that is, when the toggle switch 
returned a value of 1. 
(2) When the Introduction of FeLV toggle returned a value of 1 a connector initiated 
a difference in the time value within the Final Reticulocytes, Marrow 
Erythrocytes and Circulating Erythrocytes compartments. No other direct changes 
or viral effects were placed upon these compartments via this connection. 
 
The expression shown in (1) enabled the toggle switch to control the presence and 
absence of FeLV, and, subsequently, the infection of the BFU-E cells. This infection 
further impacted all cell compartments along the erythropoietic differentiation 
pathway by merely placing the virus action at this location. As stated earlier, the virus 
either infected the BFU-E cells (toggle switch returned a value of 1 and was turned 
on; virus was present), stopping further division and simulating cell death or was 
absent from the cells (toggle switch returned a value of 0 and was turned off). The 
loss of BFU-E cells and slope of the decline in Hct, as well as the shift of HSCs to the 
erythropoietic pathway, were then analyzed through the software’s graphical and 
animation utilities. 
 
As mentioned previously, one of the major benefits of using this particular data-
analysis software tool was the automatic assignment of differential equations to each 
part of the model. In calculus parlance, the flows represented time derivatives; stocks 
were the integrals (or accumulations) of flows over time; converters contained micro-
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 logic of flows. Having such a software tool at our disposal allowed us to concentrate 
on the overall and more important aspects of building the model. 
 
Once the model had been developed it was further tested by utilizing specific model 
validation equations. These equations will allow the demonstration of the amount of 
error found in the model and the comparison of the model BFU-E loss slope and Hct 
slope to that calculated from real system outputs.  
 
Results 
Responses to FeLV-KT Inoculation 
Of the 56 juvenile cats inoculated with FeLV-KT, 100% (56/56) became persistently 
viremic. Eighty-three percent (47/56) were viremic by 14 DPI, 96% (54/56) by 21 
DPI and 100% (56/56) by 35 DPI. Four FeLV-KT-positive cats died prior to any 
hematologic changes (one each at 17 and 19 DPI and two at 20 DPI) and exhibited 
thymic atrophy, diarrhea and generalized emaciation. 
  
Three responses to FeLV-KT infection were observed. The majority of cats, 73%, 
(30/41) expressed acute FeLV-AA (VPRC <10% within 63 DPI), 22% (9/41) 
developed a protracted form of FeLV-AA (VPRC <10% in 70 to 170 DPI) and 5% 
(2/41) developed regressive infection with no hematologic changes and in which 
latent FeLV was reactivated by in vitro culture of marrow cells. Cats that developed 
either a protracted FeLV-AA or regressive latent infection were significantly older, 
larger and produced higher titers of FOCMA antibody when compared with cats with 
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 acute FeLV-AA (Table 1; Fig. 3). Cats with protracted FeLV-AA had a significantly 
delayed onset of viremia, whereas cats with latent infection received significantly less 
infectious virus compared with cats with acute FeLV-AA (Table 1). FeLV and 
FOCMA antibody titers were significantly higher in cats with either the acute or the 
protracted response to FeLV-KT (Fig. 3; Fig. 4).  
TABLE 1. Comparison of Cats Displaying Acute, Protracted and Latent FeLV-
AA.  
                                    AGE AT                    WEIGHT AT               INOCULUM           ONSET OF 
                               INOCULATION        INOCULATION                  TITER                 VIREMIA   
                                 Days +/- SEM                 gm +/- SEM               81 cell ffu +/- SEM     days post 
                                                                                                                                                 inoculation 
 
Acute FeLV-AA*   69.80 +/- 2.3a,d        807.23 +/- 47.8a,b         9.4 x 104 +/- 1.5 x 10d    15.62 +/- 0.59c
         (n=30) 
 
 
Protracted              
FeLV-AA**         78.22 +/- 4.6a                    997.11 +/- 117.4a         8.8 x 104 +/- 3.2 x 104    18.67 +/- 3.1c  
     (n=9)    
 
 
Latent                   83.5 +/- 9.5d              1264.50 +/- 184.5b           1.5 x 103 +/- 0d              17.5 +/- 3.5 
FeLV***   
  (n=2)     
  
* VPRC <10% within 63 days post inoculation (DPI) 
** VPRC <10% in 70 to 170 DPI 
*** Regressive viremia with no significant hematologic changes 
 
a  P<0.05 comparing acute vs. protracted groups    b  P<0.05 comparing acute vs. 
latent 
                                                                                                  groups 
c  P<0.1 comparing acute vs. protracted groups      d  P<0.1 comparing acute vs. latent  
                                                                                                 groups 
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FIGURE 3. Determination of FOCMA antibody titers in cells of FeLV-KT-
infected cats. At day 7 DPI and at 7 day intervals thereafter, FeLV-KT-infected cats 
were anesthetized with ketamine hydrochloride and 2.5 ml of blood was collected 
from each. Blood was incubated with antibodies against the feline oncornavirus-
associated membrane antigen, which is known to present high titers in cats infected 
with FeLV and is frequently used as a determinant in cats that are FeLV-negative as a 
test for latent FeLV infection. Cats with acute FeLV have much higher FOCMA titers 
than those that are latently infected. 
 
       = Acute FeLV-AA           = Latent FeLV            = Protracted FeLV-AA 
 
* = P<0.05,    * = P<0.01, Student t, Ho: µLatent  = µProtracted
*   = P<0.05,    *  = P<0.01, Student t, Ho: µProtracted = µAcute
*  = P<0.05,     * = P<0.01, Student t, Ho: µAcute = µLatent 
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FIGURE 4. Determination of FeLV antibody titers in FeLV-KT-infected cats. At 
7 day intervals, FeLV-infected cats were anesthetized with ketamine hydrochloride 
and 2.5 ml of blood was obtained from each. Antibody against FeLV was used to 
determine the titer of FeLV in infected cats. Further, spleen and bone marrow 
homogenates were examined for infective FeLV using the clone 81 focus induction 
assay (data not shown).15 
 
       = Acute FeLV-AA           = Latent FeLV            = Protracted FeLV-AA 
 
* = P<0.05,    * = P<0.01, Student t, Ho:  µLatent = µProtracted
*  = P<0.01, Student t, Ho: µProtracted = µLatent
*  = P<0.05, Student t, Ho: µAcute = µLatent                           
 
 
 
Hematologic Changes 
Hematologic features of FeLV-KT-induced aplasia were identical in cats with either 
acute or protracted FeLV-AA. Protracted FeLV-AA was distinguished from acute 
FeLV-AA by a longer interval between the onset of viremia and the onset of aplasia. 
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 Once anemia commenced, the rate of VPRC decline in both groups were similar (Fig. 
5; Fig. 6). Reticulocytes, granulocytes, monocytes and lymphocytes also were 
suppressed in cats with acute FeLV-AA as compared with controls beginning 21 or 
28 DPI (Fig. 6; Fig. 7; Fig. 8; Fig. 9). 
 
FIGURE 5. Determination of the erythrocyte packed cell volume (VPRC or Hct) 
in FeLV-KT-infected cats. Responses of erythrocytes in cats infected with FeLV-
KT are demonstrated in the graph. Blood samples, collected from anesthetized cats at 
7 day intervals, were centrifuged and the red cell volume was compared with the total 
blood count and expressed as a percent. The graph shows cats with both acute FeLV-
AA and protracted FeLV-AA. Protracted FeLV-AA is displayed as the two slopes to 
the far right. 
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FIGURE 6. Comparison of the volume of packed red cells from cats displaying 
FeLV-KT infection and control littermates, which were non-infected. Data were 
obtained at 7 day intervals from infected cats and littermate control cats by 
determining the VPRC or Hct percent, as in Figure 5. Averages were calculated from 
cats displaying FeLV infection and control cats. One mg/Kg of Methyl prednisolone 
acetate was injected into each cat in both control and infected cat groups, as shown by 
the dark triangle. MPA was used to suppress effects of the immune system in order to 
determine the true percent of VPRC.   
* = P<0.01 Ho: µControl = µFeLV-AA  
         = Controls,   ----  = FeLV-KT inoculated,           = MPA 
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FIGURE 7. The comparison of red blood cell counts and reticulocyte counts in 
cats displaying acute FeLV-KT infection. Beginning at week one, continuing 
through week 8, RBC and reticulocyte cell counts were accomplished from 
circulating blood in cats with acute FeLV-KT infection. Averages are shown from all 
cats that displayed acute FeLV-KT infection. 
◘ = Reticulocytes; ○ = RBCs 
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FIGURE 8. Differential cell count (Diff) showing the Granulocyte/Monocyte 
counts of white blood cells in acute FeLV-KT-infected cats compared to 
littermate control cats. At 7 day intervals, control and FeLV-KT-infected cats were 
anesthetized with ketamine hydrochloride and 2.5 ml of blood was obtained. At the 
time of inoculation (day 0) cats received 1 mg/Kg of MPA, shown as the dark triangle 
in the figure. Control cats also received the same amount of MPA. The graph of 
lymphocytes from the differential cell counts is shown on the following page. 
Granulocytes are often named polymorphonuclear leukocytes and include 
neutrophils, eosinophils and basophils. Although not a primary target for FeLV-KT, 
the lower cell counts seen in FeLV-KT infected cats most likely corresponds to the 
shift of pluripotential stem cells to the erythropoietic pathway in an attempt to 
alleviate the loss of erythrocytes. Additionally, the lowered counts in both FeLV-KT-
infected and control cats are expected when MPA if given.  
* = P<0.01, Student t, Ho: µControl = µFeLV-AA
 
        = Controls,   -----  = FeLV-KT inoculated,         = MPA 
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FIGURE 9. Results of the lymphocyte cell counts from the differential cell 
counts of FeLV-KT inoculated cats compared to control littermate cats. At 7 day 
intervals after inoculation with FeLV-KT, both control and inoculation cats were 
anesthetized with ketamine hydrochloride and 2.5 ml of blood was collected. Both 
FeLV-inoculated cats and control cats received 1 mg/Kg of MPA at the time of 
inoculation and 7 DPI. Some suppression of lymphocytes is naturally observed due to 
these injections. The lower lymphocyte counts displayed in FeLV-KT-infected cats is, 
again, most likely due to the assumption that pluripotant stem cells have shifted to the 
attempt to relieve the loss of erythrocytes. 
* = P<0.01, Student t, Ho: µControl = µFeLV-AA
 
        = Controls,   -----  = FeLV-KT inoculated,         = MPA 
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 Hematopoietic Changes 
Abatement of marrow BFU-E was the earliest detected event in the evolution of 
FeLV-AA. A mean 19% in marrow BFU-E of inoculated cats as compared with 
controls was present at 14 DPI (Fig. 10). FeLV p27 antigen was detected in 
circulating leukocytes and thrombocytes in 93% of the inoculated cats at that time. By 
19 DPI, mean BFU-E and CFU-E were reduced by 38% and 31% respectively. At 28 
DPI, when a significant decline in VPRC was first evident, BFU-E and CFU-E were 
reduced to 20% of control values (Fig. 10). 
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FIGURE 10. The determination of erythroid progenitor cell growth in acute 
FeLV-KT-infected cats, compared to VPRC. One ml of heparinized femoral or 
humoral bone marrow aspirates from 6 inoculated cats were collected for in vitro 
assay of colony forming units – erythroid and burst forming units – erythroid. 
Marrow mononuclear cells were separated by colloidal silica buoyant density 
centrifugation (density 1.070 g/ml) and cultured. Erythropoietic® purified from the 
plasma of anemic sheep (Connaught, Willowdale, Ontario, Canada) was added to the 
cultures (0.5 units/ml). Colonies were enumerated in duplicate cultures by inverted 
phase contrast microscopy; CFU-E were counted on day 5 and BFU-E on day 11 of 
culture. The results were then compared to the VPRC. The averages from all cats 
displaying acute FeLV-KT is shown as a percent. 
 
         = Colony Forming Units - erythroid, CFU-e 
 
         = Burst Forming Units – erythroid, BFU-e 
 
▬ = VPRC  
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 Pathologic Changes 
Lesions were restricted to lymphoid and hematopoietic tissues. Histologic findings in 
marrow of aplastic cats (VPRC <10%) were marked pancytopenia with apparent 
megakaryocytic hyperplasia as compared with controls (Fig. 11). Other lesions were 
generalized pallor, thymic atrophy and pannodal lymphoid depletion (VPRC <10%). 
Consistent with the rapid depletion of lymphohematopoietic cells produced by FeLV-
KT was the absence of weight loss in cats with acute FeLV-AA as compared with 
controls (Fig. 12).    
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 a. 
 
 
 
 
 
 
 
 
 
 
 
b. 
 
FIGURE 11. Bone marrow histology of FeLV-KT-infected cats compared to 
control littermate cats. Cats were euthanized when the VPRC was less than 10%. 
Post mortem examinations were performed on all cats and duplicate tissues were 
fixed in phosphate-buffered formalin and absolute methanol for histopathology. 
Histologic findings in the marrow of aplastic cats (VPRC < 10%) were marked 
pancytopenia with apparent megakaryocytic hyperplasia as compared with controls. 
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 a. = Metaphyseal Bone Marrow from Normal Juvenile Cat. 
b. = Metaphyseal Bone Marrow From Littermate Cat with FeLV-AA. 
 
 
 
 
 
 
 
 
 
FIGURE 12. Comparison of body weights of FeLV-KT-infected cats with non-
infected, control littermates. Weights of both inoculated and control cats were 
obtained after there were anesthetized with ketamine hydrochloride at inoculation and 
at 7 day intervals, thereafter. MPA was given at the time of inoculation and at 7 DPI. 
The absence of weight loss in cats with FeLV-AA was consistent with the rapid 
depletion of lymphohematopoietic cells.  
 
        = Controls,   -----  = FeLV-KT inoculated,         = MPA 
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 Mathematical Modeling of FeLV-KT-infected Erythropoiesis 
Since FeLV-KT is specific at the level of the BFU-E, we placed the virus within this 
compartment in the model at the fifth mitotic stage (Figure 13). Our choice was 
motivated by factors previously outlined. Further, it requires time for the interaction 
of the virus with a cell surface receptor, subsequent cell internalization and 
mobilization of the virus to the nucleus and the consequential viral interruption of 
further BFU-E development.  
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 Figure 13. The Mathematical Model of FeLV-KT Infected Feline Erythropoiesis. 
The model was created to verify that viral infection at the 5th mitotic stage of BFU-E 
development creates a block, leading to death of cells at this stage and subsequent 
fatal erythroid aplasia. The death of these cells causes a loss of Hct in a characteristic 
decline that is graphically reproducible in both real-system outputs and outputs from 
the mathematical model.  
 
However, when we placed the virus in the model to interact with the first through the 
fourth mitotic stages of BFU-E development this characteristic slope of Hct was not 
shown. In fact, when cells were infected at these stages fatal erythroid aplasia was not 
demonstrated. The slope of the graph of BFU-E loss at these different points would 
initially decline but quickly recover and maintain the "normal" cell count for that 
phase of cell development. The only explanation we have for this effect is due to the 
division factor and the division times at the stages past these points. These variables 
would remain stable and may have allowed the recovery of the mitotic stage 
interacting with the FeLV.   
 
When the virus was present in the model, cells developing in the BFU-E stage were 
blocked from further erythropoietic expansion and differentiation and entered cell 
loss, or death. Data from the original experiments and logarithmic scale were 
incorporated into the computer model. By day 28, the model revealed a significant 
increase in BFU-E cell death ( Fig 14). The model FeLV-KT-infected Hct appeared 
steeper than the graph of the actual feline Hct, graphed as a percentage of the total 
packed cell count. In actuality, the slope of the loss of marrow red cells and 
circulating red cells nearly matched the average slope calculated from graphs of Hct 
decline in laboratory animals (Fig 5, 15 and 16). 
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FIGURE 14. Mathematical modeling graph of the percent cell death of FeLV-
KT-infected BFU-E. The graph displays the percent loss of BFU-E once FeLV-KT 
infection commences within the model. The graph shows the percent of BFU-E as 
they are lost after entering the fifth mitotic division stage and interacting with FeLV-
KT. The model predicts a 50% decline in BFU-E around day 30 of the infection, with 
the complete loss of BFU-E by day 70. 
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FIGURE 15. Graph of the decline of Hct in cats inoculated with FeLV-KT over 
time. At 7 day intervals, after the original inoculation, FeLV-KT-infected cats were 
anesthetized with ketamine hydrochloride and the percent of packed red bloods cells 
(VPRC) was examined. Latently FeLV-infected cats were analyzed after it was clear 
that active infection had commenced, as determined by FeLV antibody titers, 
differential cell counts, VPRC, BFU-E and CFU-E determination. Cats were 
euthanized when the VPRC or Hct was 5%. The arrow points to darkened markers, 
indicating the deaths of four cats. These cats died prior to becoming persistently 
viremic. One cat each died on day 17 and 19, while two cats expired on day 20. The 
average slope of the loss of Hct from all cats was 0.532.  
▲= MPA  ↑= cat deaths prior to persistent FeLV infection 
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Figure 16. Results of FeLV Infection upon the Hct from the Mathematical 
Model. After FeLV interacted or "infected" the BFU-E cell compartment at the fifth 
mitotic stage of development, the Hct began an immediate decline. The pink line 
represents the marrow Hct, while the green displays the circulating Hct. Circulating 
Hct begins to decline shortly after Marrow Hct, as the Circulating Hct is dependent 
on its supply from the Marrow Hct. The slope of circulating Hct was 0.543 and the 
marrow Hct was 0.5. 
 
We endeavored to embody a non-plastic system within a highly, synthetic 
environment. When a stem cell is committed to erythropoietic differentiation, the cell 
passes through 5 distinct mitoses within the BFU-E reservoir, as stated earlier. These 
take place every 8 hours. The generation time, on average, is around 24 hours, but can 
be reduced to 8 hours or prolonged to 27.22 Usually, only 33% of the cells are in the 
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 active cell cycle as compared to CFU-E, in which 100% of these cells are actively 
involved in cell cycling. 22 Within the CFU-E stage, the generation time equals the 
cell cycle time of 8 hours.22 Thus a feline requires an average of 70 days to 
completely saturate the mature red blood cell compartment. Due to the reserve 
amount of reticulocytes and red blood cells (5 x 108), once aplasia begins, a total loss 
of RBCs should develop within 70 to 140 days. Our mathematical model agreed with 
this hypothesis and supported the evidence from the original data. 
 
Model Evaluation 
 
In order to assure the validity of a working model it is important to ensure that it is 
adequate for its intended use. Various statistical tests have been incorporated for such 
model evaluation, however, these equations and tests generally prove to be incapable 
of  predicting outputs from required inputs. In practice, a test can only address the 
question of whether a model is invalid beyond reasonable doubt.23 The assumptions 
underlying the better known statistical inference techniques are rarely met when 
simulating dynamic stochastic systems, as seen within the behavior of erythropoietic 
development and virus infection in our model.23 
 
Models are not perfect and can not always mimic every aspect of biological systems. 
Therefore, models need only be adequate so some limitation of accuracy and 
precision has to be accepted.24-25 However, the model should be consistently 
reproducible. Additionally, the size of the acceptable precision can be defined with 
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 reference to the purpose of the model.24 Kohn suggested that the ambiguous analysis 
and lack of sensitivity found with regression can be overcome by using the root mean 
square prediction error (RMSPE) 25: 
 
                                 
                                                               ∑ (predicted – observed) 2    
                                 RMSPE = √                                                         
                                                                 number of observations 
 
 
This term is the square root of the estimate of variance of observed values about the 
predicted values.25 The RMSPE can be separated into its constituent parts in order to 
identify systematic problems with the model.25 In an earlier paper, Kohn et al. 
decomposed the RMSPE into two terms: the mean bias and the residual error.25 The 
mean bias represents the average inaccuracy of model predictions across all data. 
                            
                                                        ∑ (predicted – observed)                         
                              Mean bias =       
                                                             number of observations 
 
The residual error was then defined as the remaining error in model prediction after 
accounting for the mean bias.25 This error is also referred to as prediction error 
excluding mean bias. The following equation is the square root of the RMSPE 
squared minus the mean bias squared: 
                            
                             Residual error = √ [RMSPE2 – (mean bias)2] 
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 It was important to calculate the slopes of the red cell decline from the graphs of the 
real system cats and compare them to the graphs from the mathematical model. Upon 
first inspection, the graphs seemed to appear very different (Fig 15 and 16). The key 
point was to examine the slopes once EA was initiated. The Hct cell counts from each 
cat were graphed and the slope was calculated from these results. The slopes ranged 
from 0.3 to 0.929. Six of the graphs returned a slope value of 0.551 and the average 
of all slopes was 0.532. The decline in circulating Hct, from the model, produced a 
calculated slope of 0.543 and the marrow Hct declined at a slope of 0.5. When these 
results were used in the above formulas, the calculations were astounding. The 
calculation of the RMSPE, using the slope of the loss of circulating Hct to show how 
well the predictions fit the observed data, was found to be 0.002 or the model over 
predicted the loss by this negligible amount. The mean bias was calculated to 0.0004 
and the residual error was the same as the RMSPE. When the slope of the marrow 
Hct was used the resulting RMSPE under predicted the loss by 0.006, the mean bias 
was found to be 0.001 and the corrected error was shown to equal 3.5 x 10-5. While 
insignificant, this error represents a small difference between real-system outputs and 
the outputs from the computerized mathematical model. The error demonstrated that 
the model fit closely to the data obtained from experimentally-induced FeLV-EA. 
These results allow us to show conclusively that Hct declines rapidly after viral 
targeting of the BFU-E cell population. We further believe that this model can be 
expanded for the investigation of other hematopoietic queries. 
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 CHAPTER II: FLA: The Feline Major Histocompatibility Complex 
 
FLA 
The major histocompatibility complex (MHC) is a multigene complex in mammals 
that includes two distinct classes of genes. The products of these genes participate in 
immune regulation and response to foreign antigens. Class I genes encode an 
approximately Mr 45,000 cell surface glycoprotein which is noncovalently associated 
with beta-2 microglobulin on the majority of somatic cells.26 Class II genes encode α 
and β chains of a noncovalently associated heterodimeric glycoprotein expressed on 
the cell surface of lymphocytes and macrophages.26 The estimated relative masses are 
approximately 32,000 – 35,000 for the α chain and 25,000 – 28,000 for the β chain.26 
In humans there are three functional class I genes HLA-A, -B and –C clustered on the 
short arm of chromosome 6.26-29  The cat has three comparable functional class I 
genes, at this time loosely termed FLA –A, -B, and –C, found on the feline 
chromosome B2.28  
 
Of the nonprimate mammalian species with developing comparative gene maps, the 
feline gene map displays the highest level of conservation with humans.26, 28-30 
Comparison of the FLA class I coding sequence with other class I genes from other 
species has revealed that domestic cats genes display 81% to 85% sequence 
homology with humans.26, 28-31 Feline and human class I genes have similar sequences 
and protein structures, with three extracellular domains, one transmembrane domain 
and one cytoplasmic domain.28 Variable codons detected in FLA class I alleles were, 
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 in most cases, in positions that were also variable in humans.28-30  Invariant positions 
with defined functional constraints were generally conserved and invariant between 
the two species as well.28  
 
Drs. Naoya Yuhki and Stephen O’Brien, of the National Cancer Institute in Frederick, 
Maryland, have previously presented a comparison of several biochemical loci plus 
the MHC genes that are linked to chromosome B2 of the cat and chromosome 6 of 
man (Fig 2).32 The homologous genes occur on both arms of human chromosome 6, 
supporting their proof that a large portion of that chromosome is conserved as a 
 
linkage group on cat chromosome B2.32  
o detect and classify the FLA class II genes
 
T
types of mouse and four types of human class
molecular probes, from Balb/c mice, were Ad
molecules, used as probes, were DPW2α, DO
eleven cats were digested with restriction enzy
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 Figure 17. Comparison of the 
Human MHC to the Feline 
FLA. Diagram of the regional 
positions the MHC assigned to 
human and the domestic cat of 
homologous loci including 
chromosome 6 and their 
locations on the feline B2 
(FCA).32, Yuhki and O’Brien employed three 
 II DNA probes.32 The mouse class II 
α, Edα and Adβ.32 The human class II 
β, DPW2β and DR1β.32 DNA from 
mes and hybridized with each of the 
 mouse probes, while DNA from 16 cats were hybridized with the human probes. The 
DPα and DOβ detected faint bands, while the DRβ probe gave strong and consistent 
bands. Neither the mouse Adβ nor the human DPβ could detect any bands. From these 
results the group determined that FLA II has three different class II α genes: Adα 
specific, Adα, Εdα common (as these two probes cross-hybridized with a single gene) 
and DPα-like genes. They also found that the FLA II has two different class II β 
genes, the DOβ and DRβ-like genes.32 Since the mouse E class II gene belongs to the 
human DR class II gene family, it is their suggestion that the cat Adα, Εdα common 
gene may belong to the DR family.32 This relationship between human and feline 
chromosomes makes the feline an attractive model for human disease.29, 31 Dr. 
O’Brien and his laboratory staff have sequenced much of the feline genome, 
including both FLA I and FLA II. Of the 100+ disorders that have demonstrated 
Mendelian patterns of inheritance in cats, many pathologies are analogous to human 
inherited disorders and mirror the genetic locations on the genome.30 HSC 
transplantation in cats should prove beneficial both for the treatment of feline 
disorders and the examination and possible therapy for human disorders. The 
awareness of the moment when the FHSC are at their highest transplantation 
potential, through the determination of the absence of FLA, is an important first step 
to their use as effective therapy. 
 
Hematopoietic Stem Cells and Stem Cell Therapy 
Hematopoietic s matopoietic 
stem cell transplants (HSCT) are now routinely used to treat patients with cancers and 
tem cells have been studied for more than 50 years. He
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 other disorders of the blood and immune systems. In animal studies, researchers hav
recently observed that HSC appear to be able to form other kinds of cells, such as 
muscle, blood vessels and bone.
e 
 immune cells are the HSC. They are ultimately 
responsible for the constant renewal of billions of blood cells each day. The first 
och 
 for 
r experience with HSC, there are serious roadblocks to the success of their 
use, not only as therapy for the replacement of blood and immune cells, but in 
ailure 
e 
-
nt 
33 It may be eventually possible to use HSC to replace 
a wider array of cells and tissues. 
 
The stem cells that form blood and
evidence and definition of blood forming stem cells came from studies of people 
exposed to lethal doses of radiation in 1945.33 In the early 1960s, Till and McCull
began analyzing the bone marrow to find out which components were responsible
regenerating blood.34 They defined what remain the two hallmarks of an HSC: it can 
renew itself and it can produce cells that give rise to all the different types of blood 
cells.33-34 
 
Despite ou
expanding their use beyond this. First, transplantation of allogeneic marrow cells 
from alternative donors has usually resulted in an increased incidence of graft f
and/or GVHD. These problems have depended upon the source of the graft and th
use of ex vivo manipulation to deplete T-cells as prophylaxis against GVHD.35-42 
However, not only do a high percentage of patients still show signs of GVHD, but T
cell depletion increases the risks of viral infections, relapse of disease post transpla
(probably due to the parallel abrogation of a potentially beneficial graft-versus-
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 leukemia effect) and graft rejection.35, 38-39.41-42 Second, isolated HSCs in vitro are 
unable to proliferate and differentiate. 
 
The classic source of HSC as transplant therapy has been the bone marrow. For over 
40 years, bone marrow transplants (BMT) have been performed by anesthetizing the 
y fading, as the harvesting of donor cells from 
eripheral, circulating blood has now become the major source of HSCs for clinical 
e 
 5 
d 
d blood and placenta are a rich source of HSC, however they yield only 
a very small amount. The first successful umbilical cord blood transplants were 
 
stem cell donor, puncturing a bone (typically the hip bone) and drawing out bone 
marrow cells with a syringe. Only one cell in 100,000 cells in the marrow is a long-
term, blood forming stem cell. 
 
Bone marrow retrieval is quickl
p
transplantation. Only a small number of stem and progenitor cells circulate in th
bloodstream. This number can be increased by injecting the donor with a cytokine, 
such as granulocyte-colony stimulating factor (GCSF). Of the cells collected, only
to, very rarely, 20 percent of these are true HSC.33,35 Although peripherally harveste
cells engraft more quickly than bone marrow, they are more likely to cause 
GVHD.33,35  
 
Umbilical cor
performed in the late 80's and early 90’s in children with Fanconi anemia.43 Because 
the amount of cord blood collection is small, the majority of recipients receiving
umbilical cord blood transplants are children.43-44 Although GVHD incidence is 
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 lower, this may be due in large part to the fact that children have a lower overall 
incidence of GVHD.43-44 Additionally, there is evidence that maternal cell 
contamination exists in cord blood collections, posing a serious threat to adult 
recipients of cord blood transplants.43-44 
 
Unlike HSCs from the other sources, fetal HSCs, before a certain gestational point, 
lack MHC cell surface determinants, thereby avoiding GVHD, have a greater ability 
 
, 
 cells 
gainst leukemia and lymphoma, 
inherited blood disorders, rescue in cancer chemotherapy and may be useful for other 
to self-replicate and readily lend themselves to gene insertion and manipulations.33,44
European researchers have shown that the relative number of CD34+ cells (a cell 
surface marker denoting a cell as an undifferentiated stem cell – see below) in 
collections declined with increasing gestational age.45 In fact, in studies with mice
cells from fetal mice were 50 to 100 percent better at repopulating marrow than
from either juvenile mice or young adult mice.33      
 
HSC transplantation has been used for therapy a
disorders such as diabetes, lupus erythematosis and rheumatoid arthritis. Currently, 
the use of HSCT is restricted to patients with fatal or near fatal illnesses due to the 
serious risks involved. These risks are GVHD, graft rejection and life threatening 
infections during the period before HSCs have engrafted and resumed full blood cell 
production. Allogeneic grafts must come from donors with a close HLA match to the 
patient.44 This match is not always available and, thus, many patients are unable to 
benefit from HSCT. Additionally, even in patients who receive an HSCT from an 
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 HLA-matched sibling, GVHD still poses a severe threat due to minor 
histocompatibility antigens and pre-treatment with immunosuppressants.44 Therefore, 
the knowledge of when the MHC first appear on the surface of these cells will enable 
transplants to be used without the risks involved and given to a broader range of 
patients. The benefit of this study in cats is that they share a high genetic homology to 
humans. This study will not only benefit cats, but there is direct correlation to studies 
in humans, which will further the research of human FHSC. 
 
Immunophenotypes of Mammalian HSC 
ll cellular elements of blood, including white blood cells, red blood cells, T-cells, 
etc., arise from a com n point in human 
 
d 
 until 
 
A
mon precursor cell, the HSC. Before a certai
gestation, the HSC are absent of any cell surface markers.46-47 CD34, a stem cell 
marker, has been identified and characterized in humans, dogs, cats and mice.46-47 In
non-human primates, monoclonal antibodies to human CD34 are cross reactive an
identify a population of stem cells.47-48 Additionally, c-kit and Ly-6A/E (or Sca-1) 
have been identified as stem cell markers in mice.47,49,50,52 C-kit molecules are cell-
surface receptors on bone marrow cell types that identifies HSC and mesenchymal 
stem cells (MSC), while Sca-1 is a cell-surface protein on bone marrow cells, 
indicative of HSC and MSC.50,52 These cell surface proteins distinguish more 
primitive hematopietic cells from lineage-specific cells.51-52 Other cell surface 
molecules, such as IL-7R are absent from the surface, as they are not expressed
the cell has been committed to a specific cell lineage.52 
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 The CD34+ antigen is a 115 kDa surface glycophosphoprotein, expressed on 1-3% of
normal bone marrow cells.
 
e human bone marrow 
D34+ cell compartment contains primitive multipotential hematopoietic cells, 
 
nd 
e 
 that 
 in 
 
e 
se 
is 
53 In vitro data suggest that th
C
responsible for both short- and long-term repopulation.54 In humans, the CD34+ 
hematopoietic stem cell surface marker begins to be expressed on the surface of
lymphohematopoietic cells around the 8th week of gestation.46 A recent study fou
that the development of human lymphohematopoietic stem progenitor cells may b
defined by CD81, as well as CD34.55 They found that lymphohematopoietic cells
expressed CD34lowCD81+ were committed to differentiation, having lost most of 
their long-term repopulating (LTR) potential, although cells that were CD34+ and 
CD81+ still had all their lymphohematopoietic properties.55 Therefore, in addition to 
using the appearance of FLA on the cell surface, CD81 may serve as a marker for 
defining the developmental stages of lymphohematopoietic cells and may be useful
the future for determining when these cells are at their highest repopulating potential. 
Stem cells are very rare, representing less than 0.01% of all nucleated cells in the 
normal bone marrow. Based on animal experiments, the morphology of HSC is 
thought to be similar to that of small lymphoid cells.56 Human HSC express the 
surface proteins CD34+ and c-kit and are negative for CD38 and lineage specific 
markers.56 From the pluripotent progenitor HSC, more specialized progenitors ar
formed. Under normal conditions, the majority of stem cells are dormant (G0 pha
of cell cycle). A stem cell only divides to maintain the steady state of hematopoies
or to meet the body’s demand for progenitor cells (stochastic model of 
hematopoiesis).56 CD34 is expressed at highest levels on the earliest hematopoietic 
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 cells and its surface expression dramatically decreases to undetectable levels 
progressively during maturation.49,56 In addition, these stem cells retain 
ability and option of giving rise to cells of all lineages.
for life the 
c bone 
his project is the hope that fetal feline 
ematopoietic stem cells (FHSC), once pooled, can be used as “universal donor” 
cells. If the point in gestatio Cs lack FLA but display a 
 a lack of 
ses 
 
The extraordinary survival mechanisms of 
e virus have allowed us to merely delay the onset of the fatal acquired 
33,47,49 Stem cells, from 
unrelated donors, can be engrafted in bone marrow of individuals whose 
hematopoietic cells have been depleted by disease or treatment, giving rise to the 
entire architecture of hematopoietic cells and this forms the basis for therapeuti
stem cell transplantation.33,43,47,49 
 
Clinical Utility of Stem Cells 
One of the driving forces behind t
h
n can be determined, when FHS
high population of CD34+ molecules on the cell surface (an indication of
“self” cell- or immune- surface proteins) then these cells can be obtained from fetu
of this determined age and utilized for either gene therapy or administered where a 
marrow transplant is indicated but no suitable donor exists. The use of FHSC, 
endowed with genes to inhibit FIV replication in cats is one important study that 
would benefit from this proposed research, leading to an animal model for the study
of effective HIV treatment strategies.    
 
Human immunodeficiency virus (HIV) has, to date, succeeded in evading existing 
therapies and novel anti-viral strategies. 
th
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 immunodeficiency syndrome (AIDS) and have dealt a devastating blow, both in ter
of the loss of lives and in draining individual and government financial resources. 
Infection of domestic cats with feline immunodeficiency virus (FIV) prov
excellent animal model for investigating the mechanisms of pathogenesis and for the 
development of effective antiviral therapies and vaccines for humans infected with
HIV.
ms 
ides an 
 
63-70 Evidence of the relative ease of 
cceptance of marrow grafts is seen in the lower incidence of acute or chronic graft-
-75% in humans, 
ter-mate 
e 
tion and AIDS 
ogenesis. The following table compares and contrasts the conceptual differences 
57-62 FIV is associated with immunosuppression and an acquired 
immunodeficiency syndrome (feline AIDS). The clinical course of FIV infections 
parallels that seen in HIV infection.58-62 
 
 A number of laboratories have noted how well suited cats are for 
lymphohematopoietic transplant studies.
a
versus-host disease (GVHD) in cats (approximately 20% versus 50
dogs and primates) and reports of performing allogeneic transplants across lit
boundaries.67, 71-72  One major focus of this work was to isolate these cells prior to th
expression of FLA, thereby avoiding the complications of GVHD.  
     
The ultimate goal in AIDS research is to develop effective strategies that can inhibit 
HIV gene expression or function and consequently limit HIV replica
path
between conventional drug approaches and the promise of hematopoietic stem cell 
gene therapy:57
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  Antiviral   Stem  
                Type of Therapy     Drug 
      Rx 
   Cell 
Gene Rx    
         Life-long Administration      Yes      No 
          Systemic Drug Toxicity      Yes      No 
         Drug compliance Issues      Yes      No 
Drug Cytotoxicity to Lymphohematopoietic Cells      Yes      No 
Protection all Blood, Lymphoid and Macrophage Cell       No     Yes 
Lineages 
    Life-long Cellular Prophylaxis       No        ? 
Retrovirus Strains Become Resistant      Yes        ?  
 
Table 2. Comparison of the effects of traditional antiviral treatments versus stem 
 
Successful introduction of foreign genes into hematopoietic stem cells, in animals, 
will help the design of strategies to develop targeted inhibition of HIV replication in 
infected individuals. Hematopoietic tissues contain small populations of primitive, 
totipotent stem cells capable of self-renewal and of generating committed progenitors 
of all the different myeloid and lymphoid compartments.  In the developing feline 
fetus, the liver is a primary hematopoietic organ and a rich source of HSC. The HSC 
are, therefore, excellent vehicles for gene therapy. Many laboratories have 
demonstrated successful gene transfer into hematopoietic progenitor cells. The ability 
to harness the power of HSC will come through avoiding problems arising from 
transplantations and marrow grafts. Such problems can be avoided if we know when 
these cells first display histocompatibility markers. 
 
 The fact that feline FHSC could demonstrate such reconstitution and serve as 
“universal donor” cells is a very real possibility. FHSC, before a certain gestational 
cell gene therapy.  
73-75
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 age, are either only slightly endowed with major histocompatibility antigens, class I 
 high 
but no 
hages, which are protected against HIV, has many advantages 
ver existing therapies for HIV/AIDS. The ability to molecularly protect cells has 
 
 
ay 
 
 
 
and class II, or these antigens are completely absent. As well, these cells have a
population of CD34+ molecules, indicative of hematopoietic and long-term 
repopulating potential.75-77 If such a gestational time point can be determined when 
the FHSC are at their highest long-term marrow repopulating capacity, then these 
cells can be pooled and administered where a marrow transplant is indicated 
suitable donor exists.  
 
Endowing a patient with FHSC that will provide a life-long source of lymphocytes 
and monocytes/macrop
o
been accomplished by a number of laboratories in a variety of in vitro systems.44, 76-79
One of the impediments to applying this therapy successfully is transferring the 
particular protective genes into a sufficient percentage of hematopoietic stem cells.
Using FHSC may allow a significant increase in the gene transfer to HSC. The 
establishment of a system of transplanting cats with FHSC will be a more rapid w
to evaluate other in vivo combination HIV/AIDS therapies because of the fortuitous
synergy of feline transplantation biology, the availability of a limitless supply of
FHSC and the virologically relevant FIV model system. Therefore, it is important to 
determine when, in gestation, the FHSC lack the FLA cell-surface proteins and are at
their highest marrow repopulating potential.  
 
 55 
 
 Transplantation of allogeneic marrow cells from alternative donors has usually 
resulted in an increased incidence of graft failure and/or GVHD, depending on the 
urce of the graft and the use of ex vivo manipulation to deplete T-cells as 
enous 
, 81 
), 
of their self-renewing pluripotentiality, 
re not dividing and are reluctant to accept new genes, may find the answer in the 
 large 
g 
or FIV in 
iding a model for the study of novel HIV therapies, but also may 
ad to the treatment of FeLV in cats. FeLV has been compared to the human 
retrovirus, HTLV-III, studies of which would benefit from comparative FeLV studies. 
so
prophylaxis against GVHD. 37, 44, 77-78, 80 Studies have demonstrated that an exog
gene can be expressed in feline hematopoietic cells after reconstitution of lethally 
irradiated donors with retroviral-infected autologous bone marrow.435-37, 67-68
Studies of FHSC transplantation in cats can more rapidly evaluate therapeutic 
strategies due to the abundant supply of feline fetal hematopoietic stem cells (FHSC
assisted by the fact that cats are multiparous. 
 
The issue of solving the problem of how to transfer genes to a miniscule 
subpopulation of marrow cells that, by virtue 
a
unique resource of the FHSC.37-42, 82-83 This population of cells contains a
quantity of stem cells, lacking FLA markers. Moreover, they are receptive to gene 
insertion because they are dividing at a rapid rate to achieve their mandate of givin
rise to a replete and functional lymphohematopoietic system by the time of 
paturation.84-88   
 
Gene therapy using FHSC may not only hold the key to successful therapy f
cats, thereby prov
le
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 Because the virus targets the BFU-E, the transplantation of FHSC endowed with 
genes protected against this targeted attack, may be a very real means of inhibiting 
further viral replication and its ability to block red cell development.    
 
Armed with an unlimited supply of lymphohematopoietic cells coupled with
knowledge of the sequence of the FLA, antibodies to feline CD34 and to the FLA, t
determination of a gestational point, when these cells are at 
 the 
he 
their highest 
ansplantation potential, is not only possible but carries the greatest probability of 
en relocates to the bone marrow.89 The liver of the fetus is the primary 
However, before 19 days, all hematopoiesis takes 
place within the yolk sac.89 Wh loped liver only display MHC 
tr
success. These cells will either lack FLA or have a low percentage of FLA on their 
cell surface. Additionally, these cells should display a high percentage of CD34+ 
molecules. 
                                                     
The Fetal Feline Liver 
During feline ontogeny, hematopoiesis commences in the yolk sac, proceeds to the 
liver and th
gestational hematopoietic organ. 
ile cells in the fully deve
I, the evolving fetal liver, at around 20 days, is composed of 80% transient 
hematopoietic cells that will eventually display the FLA surface proteins.27, 32, 89 
Many of the erythroid progenitor cells are already expressing their cell surface 
markers by the 25th day of gestation, making the majority of these cells useless as a 
source of a marrow transplant repopulating tool. Despite this, the liver does not take 
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 over a large percentage of hematopoiesis until it is fully formed, which happens 
slowly between the 30th and 46th day of fetal development.89  
 
Substantial evidence has accumulated indicating the existence of stem cells in the 
liver.  In ontogeny, hepatoblasts have the ability to differentiate into hepatocytes and 
iliary cells.89, 90-91 As the organ develops, cellular terminal differentiation occurs and 
 as partial hepatectomy. It is unclear the quantity and form of hepatic 
rogenitor cells which could exhibit unique characteristics promoting novel 
b
there appears to be an inverse relationship between cellular differentiation and cell 
proliferation.91 
 
However, the liver is a unique organ in the capacity to regenerate after specific forms 
of trauma, such
p
therapeutic approaches in, for example, hepatocyte transplantation, gene therapy and 
artificial liver assist devices.90  Thus, the identification and characterization of fetal 
hepatic progenitor stem cells could have a substantial impact on current experimental 
therapies for human liver disease.90-91 Additionally, information regarding the first 
expression of cell-surface antigens will greatly enhance the knowledge of when these 
fetal liver cells are at their highest therapeutic potential. Fetal liver HSC have found 
success in the treatment of fatal blood disorders, by transplantation of these cells into 
the bone marrow.90-92 Recently researchers at the Institute of Clinical Medicine, 
University of Tsukuba, Ibaraki, Japan discovered that hepatic stem/progenitor cells 
with high proliferative potential exist in the developing mouse liver, which can be 
enriched by using flow cytometry.91-92 
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 Determination of the Appearance of FLA on the Surface of Fetal Liver Cells 
Specific Aim 
What is the gestational time point w
 
hen genotypically unique FLA proteins first 
ap e 
loss of the long term repopulatin these cells, as seen through the 
 lose their totipotency and gain 
ell surface proteins and antigens that determine the cellular and organ niches they 
will inevitably fill. The gain and l e cell surface determinants occurs 
pear on the surface of fetal feline stem cells? Does this time point coincide with th
g potential of 
downregulation of CD34-like cell surface antigens? 
 
Rationale 
During fetal development, hematopoietic stem cells
c
oss of thes
through an orchestration of genes in concert with the loss of naiveté of the cell. As the 
HSC move from the yolk sac to the liver, the production of specific blood cell types is 
controlled by HSC programming. While hematopoiesis takes place in the liver, some 
of these cells leave the liver, migrate to the bloodstream and enter the thymus as T 
stem cells where they eventually become T-lymphocytes. However, it is not known at 
what stage of fetal development these cells lose their totipotency and express antigens 
that show they have been constrained to a specific cell lineage. The ability of these 
cells to repopulate the lymphopoietic architecture from one feline to another is 
complicated by the expression of major histocompatibility antigens on the surface of 
the HSC. To pool these cells for use as a therapeutic tool it is important to know when 
the FLA are first expressed on the surface of HSC in the liver. This knowledge will 
allow future therapeutic options to avoid the complications of Graft-versus-Host-
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 Disease. Here we show that FLA appear on the surface of the HSC within the liver as 
hematopoiesis moves from the yolk-sac to the liver around day 40 in feline gestation.  
 
Methods 
Livers from 10 day-old to 60 day-old feline fetuses were obtained from 
ovariohysterectomies. Local veterinarians were instructed to collect gravid uteri after 
performing pregnant spays. The gravid  placed in a sterile bag and 
moved from 
n and 
, 
e 
onoclonal antibody (ovine anti-MHC I 
 uteri were
refrigerated at -4o C. Once the samples were received, the fetuses were re
the gravid uteri and placed in formalin or the -70o C freezer. Tissues (whole fetuses 
and fetal livers) were embedded in O.C.T. compound, frozen in liquid nitroge
stored in -70o C until they were stained. 16 gauge (16G) and 17G injection needles 
were blunted and sharpened with a grinding machine. The 17G needle was used to 
punch paraffin wax cylinders, which were 3 mm in height and 2 mm in diameter, 
creating a matrix of cylinders on a paraffin block. One block contained 42 cylinders
while two others contained 30 cylinders. The 16G needle was used to obtain tissue 
cylinders from 70 paraffin-embedded whole livers and fetuses, some of which wer
from the same litter. These tissue samples were injected into the blank paraffin wax 
block. Sections between 4-6 µm in thickness were cut using a Micron HM500 
cryostat and mounted onto Superfrost® microscope slides. The smaller diameter 
(17G) of the needle used to punch the blank wax paraffin block allowed the bigger 
tissue cores to fit easily into the blank.  
 
The expression of FLA molecules on the surface of feline fetal hematopoietic stem 
cells within the liver was determined using a m
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 IgG 1) in a biotin-strep-avidin immunohistochemical technique. The paraffin was 
n 
e 
led that the protein determinants of self recognition began to be 
isplayed on the surface of cells, within the fetal liver, around day 40 of feline fetal 
gestation.  As well, early analysis suggested that the expression of the MHC I 
D34+-like cells (HSC) than the liver of 20-day-
ld fetuses. The percent of CD34+-like cells in the liver increases from 0.17% in 20-
removed and the slides were dehydrated in a standard technique. The slides were 
treated with an antigen retrieval solution (DAKOCytomation) and a biotin block prior 
to incubation with the primary antibody, sheep anti-MHC I IgG 1, at a concentratio
of 1:400. These antibodies were known to cross-react in a strong manner with felin
Class I MHC antigens93. After rinsing, the slides were treated with the secondary 
antibody, mouse anti-cat, at the same concentration as the primary antibody. The 
slides were then exposed to a blocking reagent, enzyme and substrate and 
counterstained.   
 
Results 
The results revea
d
increased as the fetus neared birth. The fact that MHC I was expressed at this time 
point was startling, given the knowledge that hematopoiesis moves from the yolk sac 
to the liver at that same time point.  
 
Prior studies in our laboratory revealed that the yolk-sacs of 20-day-old fetuses 
contain 10 times the percentage of C
o
day-old fetuses to 0.92% on day 30, to 4.22% on day 46%, declining to 3.81% 
thereafter, as the fetus nears term. The percent of MHC Class I antigens revealed that 
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 an average 95.8% of the cells were expressing the protein by day 58 (figures 18 and 
19).  These results suggest that cells in the fetal liver, although containing a low 
percentage of HSC, may still provide enough cells to be pooled for use in transplant 
therapy prior to day 40. 
The following figures demonstrate the results of cell staining with anti-sheep MHC 
class I antibodies. Figures 18 and 19 showed diffuse staining of cells within the fetal 
feline liver with the anti-MHC I antibody. The fetuses were around day 58 (from day 
56 to day 58) of gestation in both of these photos. Figure 20 and 21 displayed the 
negative results of staining a fetal liver sample with the anti-sheep MHC I. The 
fetuses, from which these last samples were collected, were 21 and 32 days old, 
respectively.  
 
FIGURE 18. Positive results of immunohistochemical staining with anti-MHC 
Class I on a 58 day old feline fetal liver. A tissue array core of a fetal feline liver 
was stained with anti-sheep-MHC Class I. The results show diffuse staining of cells 
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 within the liver of a 58 day old feline fetus, indicating that 94.2% of the cells were 
expressing MHC Class I the cell surface. Positive staining is revealed by the dark-red 
color seen on cells within the sample. 
 
 
Figure 19. Positive results of immunhistochemical staining with anti-MHC Class 
I on a 58 day old fetal feline liver. A core sample taken from a 58 day gestational 
etus was stained with anti-sheep-MHCf
r
 Class I antibodies at a dilution of 1:400. The 
esults show diffuse staining of the cells in the liver, demonstrating that 97.4% of 
cells were expressing MHC Class I cell surface. 
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Figure 20. Negative results of immunhostochemical staining with anti-MHC 
Class I on cells within a feline fetal liver sample. Whole liver sample, removed 
from a 21 day old fetus, was stained with anti-sheep-MHC Class 1 antibodies at a 
dilution of 1:400. The results show that no MHC Class I proteins are expressed on 
cells within the fetal liver at this stage in gestation. 
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Figure 21. Negative results of immunohistochemical staining of a 32 day old 
feline fetal liver with anti-MHC Class 1. A tissue core sample from a 32 day old 
feline fetus was stained with anti-sheep-MHC Class I at a dilution of 1:400. No 
expression of MHC I is seen on the cells in this sample. 
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 CHAPTER III: Feline Studies and the Relation to Human Studies 
Human Immunodeficiency Virus 
The research performed, herein, is both timely and topical. As the number of AIDS 
cases climb every year, it is clear that there is a need for a model to enable researchers 
to study the mechanisms of pathogenesis and have a model by which to study the 
development of effective antiviral therapies and vaccines. Cats are being recognized 
as a rich biomedical resource that has retained a high degree of genetic homology 
with humans than all other non-primate species. The discovery and characterization 
of a horizontally transmitted retrovirus (FIV) will facilitate our understanding of HIV 
and the therapies employed to treat AIDS, allowing researchers to help cats and 
Stem cell research was heralded in 1999 as the biggest scientific breakthrough of the 
year, holding the promise of treatments and even cures for a wide host of diseases and 
physically disabling conditions via HSC transplantation. Cats are well suited for HSC 
transplantation. They are large enough to sample while small enough to house. Feline 
investigations are inexpensive compared to al models, 
particularly primates. Their fastidious grooming habits and stoic temperaments are 
likely contributors to the lower incidence of fecal oral contamination seen in other 
species of HSC transplant recipients, namely canines and primates.  
 
Similar to HIV, the FIV genome contains several open reading frames (ORFs) in 
addition to genes encoding the structural proteins.93-94 These additional ORFs include 
humans. 
 
 those of other larger anim
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 the rev s 
replication.76-77, 79, 93-94 Th  vif gene have revealed 
 
 
IV 
rovides multiple targets to inhibit different stages of viral replication.93-94 
n of clonogenic 
rogenitor cells are defined by methycellulose assays has been reported to be in the 
e 
and vif genes and orf A.93-94 The FIV rev gene product is critical for viru
e introductions of mutation(s) in the
that this auxiliary gene product is important for efficient viral replication.76-77, 79, 93-94
Furthermore, an unusual RNA-folding region that is required for REV (RRE) has 
been identified at the end of env.76-77, 79, 93-94 This region reveals a structure that is 
highly conserved among several FIV isolates. FIV replication is dependent on the 
fully functional Rev protein and RRE for productive replication.76, 93-94 Therefore, 
similar to HIV, regulatory regions and auxiliary genes of FIV can also be targeted as
anti-viral strategies to inhibit virus replication.76-78, 93-94 Since targeting multiple 
regions helps safeguard against viral escape mutants, the additional ORFs in the F
genome p
 
Successful introduction of foreign genes into HSCs in animals will help scientific 
progress toward not only developing targeted inhibition of HIV replication in infected 
individuals, but also treatment of genetic blood disorders and cancers of the blood. 
Hematopoietic tissues contain small populations of primitive, pluripotent HSCs 
capable of self-renewal and generating committed progenitors of all the different 
myeloid and lymphoid lineages.43, 75-76 Therefore, HSCs are excellent vehicles for 
gene therapy.38, 43  HSCs in the adult bone marrow are few in numbers and 
quiescent.38, 75, 80 In many cases, mediated retroviral gene transductio
p
range of 2-20%.76-78, 94 In addition, the level of gene marking drops when HSCs ar
maintained in long-term culture, suggesting that different populations of progenitor 
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 cells, as defined by in vitro activity, are marked with different efficiencies.78-79, 82, 94
In rhesus monkeys, cats and dogs reconstituted with transduced bone marrow cells, 
retroviral vectors have been detected in lymphoid and myeloid lineages more than 
one year after transplantation, suggesting successful stem cell gene transfer. Despi
this, the percentage of marrow-derived cells containing the transferred gene is 
generally only 0.1-1%.
 
te 
 
Practicing veterinarians are routinely asked to perform complete 
ovariohysterectomies (spays) on pregnant cats or they discover a cat is pregnant while 
performing an elective spay. These valuable sources of FHSC are normally discarded. 
Having such an abundant supply of stem cells opens the door for large variety of 
scientific studies. FHSC before a gestational age are only slightly endowed with HLA 
antigens, have a high proportion of CD34+ molecules and have T-cells that exhibit 
thymic naïveté.  These cells have been shown to elicit significantly less graft-
versus-host-disease than bone marrow when used for transplantation. 
 
Graft-versus-Host-Disease and Transplant Therapy 
GVHD is a serious complication that arises frequently following allogeneic HSC 
transplantation (HSCT). Despite all of the advances and new drug therapies, GVHD 
remains a major problem in children and adults. The incidence of GVHD varies from 
9 to 76% and the mortality can be as high as 50%.  The disease occurs when T cells 
from donor bone marrow or peripheral blood stem cells (PBSCs) mount an 
47-48, 63, 65, 67, 70, 94 In order for stem cell gene therapy to 
effectively inhibit HIV replication, a much higher percentage of stem cells must be
highly stable when transferred.  
 
35, 73-75
35, 38-40, 42 
44
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 immunological attack on host tissues. GVHD classically affects the skin, liver, GI 
tract and the immune system.44, 95-96 Additionally, the mucous membranes, airway an
bone marrow may also be involved. The two types of GVHD, acute and chronic, ar
both associated with significant morbidity and mortality. Acute disease is graded 
from 0 (none) to IV (life-threatening).
d 
e 
 the 
 have a 
CT incur GVHD at a rate of 79%.43-44 In Japan, the 
cidence of transfusion-associated GVHD is estimated to be 1 in 500 open heart 
operations.
 
Treatment for acute GVHD, which occurs within two weeks of HSCT, is usually 
accomplished through the use of corticosteroids and/or antithymocyte globulin, but 
the response rate to therapy is unsatisfactory.  Despite prophylaxis with cyclosporin, 
frequently combined with methotrexate, and use of a donor (usually a sibling) 
matched at the MHC gene complex, the risks for developing GVHD are quite high.44, 
 In children, GVHD is responsible for one-quarter of the deaths observed after 
this procedure, even when stem cells from an HLA-matched sibling and prophylactic 
treatment are received.   
Long term survivors of allogeneic HSCT are not free of the threat of GVHD. Chronic 
GVHD can develop and is the major cause of death in these individuals.  
Progressive chronic GVHD evolves directly from acute active GVHD and carries a 
very poor prognosis.  There is also a quiescent form of the disease, which 
43-44 The overall grade of GVHD predicts
clinical course and prognosis. However, even patients with a grade 0 or I only
56% survival rate, which decreases significantly with grades II through IV.43-44 
Adults over age 50 receiving HS
in
43-44 
95
95-97
95, 98
95, 99
44, 95, 100
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 develops after resolution of acute GVHD.44, 95, 99 De novo chronic GVHD develops
without any prior history of acute GVHD.
 
ce 
y, is highly nephrotoxic.97-98 While T cell depletion is one of the 
ost effective means of preventing GVHD, it is associated with delayed immune 
 
vors of 
 
 these cells offer the hope of HSCT without the severe 
es hope 
44, 95, 99 As well, GVHD is not always due to 
histo-incompatibility between donor and recipient. Inappropriate recognition of self 
antigens can occur post HSCT, causing a GVHD-like syndrome 44, 95-96 
 
The agents used as therapy, against GVHD, are sadly unsuccessful and are associated 
with severe toxic effects. Even the new use of the macrolide antibiotic and 
immunosuppressant, tacrolimus, showed no improvements in overall or disease-free 
survival.44, 97-100 Additionally, tacrolimus, like cyclosporin, the major drug of choi
in GVHD therap
m
reconstitution, ensuing infectious complications and, frequently, the recurrence of
leukemia.97-100 These problems are major drawbacks that can reduce or even 
obliterate the advantages offered by T cell depletion.44, 97, 100 It has been observed that 
chronic GVHD is the main cause of morbidity and mortality in long term survi
HSCT.44, 96, 100  
 
Despite the fact that fetal stem cells can be endowed with genes to protect against
various retroviral infections,
life-threatening complication of GVHD. If these cells can be pooled and used in 
various forms of therapy, they truly will be “universal-donor” cells. This giv
for better HIV protection and treatment for AIDS patients.   
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 Future Studies 
Expanding the Mathematical Model 
A mathematical model is a conceptual model that takes on the role of a real worl
problem using mathematical language, rather than ordinary languages
d 
 to express a 
articular scientific concept. Models are necessarily simplistic descriptions of an 
cts which 
s 
y 
rld. 
s or 
, it 
tained if 
ing the mathematical model of FeLV-infection, it was hoped that 
ventually it could be expanded to produce a two-disease model, as was originally 
ere direct results of the 
fection of the BFU-E by FeLV-KT, as secondary effects or if these were, in fact, 
p
actual context. Ordinarily, a model represents what are believed to be a few crucial 
features of this context and achieves simplification by omitting other aspe
are less important or are irrelevant. The danger, of course, is that something that i
crucial may be left out. The obvious strengths of mathematical models are that the
use mathematical languages to describe a given scientific context in the real wo
This permits a high degree of precision in the statement of descriptive hypothese
assumptions. It also facilitates the logical manipulation of the statements. Finally
often provides quantitative (i.e., numerical) conclusions that may not be ob
natural languages are used to describe the scientific context.  
 
When construct
e
created by Dr. Irwin D. Bross. Dr. Bross developed a two-disease model of breast 
cancer in the 1980’s, in which he used data gathered from laboratory experiments to 
reveal two different types of breast cancers.101 As we know there are three forms of 
FeLV, it was hoped to show a two-disease model using FeLV-A and FeLV-KT to 
assist in determining if neutropenia and myelosuppression w
in
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 due to infection with FeLV, Subg ifically hope to later expand this 
model to analyze real s  FeLV-A. This model 
 progenitors are shared 
y CD34+CD81+ and CD34(Low)CD81+ populations, but multipotential progenitors 
roup A. We spec
ystem outputs of SPF cats infected with
will then be coupled to the model for FeLV-KT to analyze the loss of white blood 
cells, allowing us to see if neutropenia is truly a secondary effect or if FeLV-KT must 
arise de novo with cats infected with FeLV-A.  
 
Expanding the Antibody Studies 
Human blood cells, except for erythrocytes and platelets, express CD81, a member of 
the transmembrane 4 superfamily (TM4SF). CD81 is also expressed on most of 
human immature hematopoietic cells, CD34+ cells, which are divided into three 
populations according to the expression of CD34 and CD81; CD34+CD81+, 
CD34+CD81(High) and CD34(Low)CD81+. Myeloid and lymphoid progenitors exist 
in the CD34+CD81+ population, and megakaryocytic progenitors are only in 
CD34(Low)CD81+ population. Erythroid and multipotential
b
in the CD34+CD81+ population have already lost most of their myeloid potential. 
NK cells and mast cells can be generated from all three populations. Long-term 
repopulating (LTR) lymphohematopoietic stem cells are present in the CD34+CD81+ 
population.102 Thus, along the differentiation cascade from CD34+CD81+ 
lymphohematopoietic stem cells, an up-regulation of CD81 or a down-regulation of 
CD34 results in a change in lymphohematopoietic properties. CD81 may serve as a 
marker for defining developmental stages of lymphohematopoietic stem cells.103  
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 It is not known if feline lymphohematopoietic stem cells express the CD81 antigen. It 
is also not know how the expression of MHC I on these cells may correlate with 
CD81 expression. Future research is envisioned that would determine whether felines 
express a CD81-like antigen on the surface of lymphohematopoietic stem cells. The 
following questions could arise from identifying a feline CD81-like antigen: 
Is it possible to change the expression of CD81 on these cells and does such a 
change cause the LTR
- 
 of these cells to remain high?  
- Additionally, does the particular change in the regulation of CD81 effect the 
expression of MHC I or MHC II? 
- Does the movement of hematopoiesis from the yolk sac to the liver have any 
effect on the expression of CD81. 
 
The expansion of the research within this document could assist in the development 
of better modeling systems to determine treatment efficacy, as well as leading to more 
efficient, less physically-devastating treatments, overall.                                     
 73 
 
 References 
1. Mackey L. 4 January 1975. Feline leukaemia virus and its clinical effects in cats. 
Vet. Rec. 96(1):5-11. 
2. Cotter S.M. 1979. Anemia associated with feline leukemia virus infection. J.  
      Amer. Vet. Med. Assoc. 175:1191-1194. 
 
   
  
      
      ia virus. J. Natl. Cancer Inst. 53:1271-1276. 
       Natl. Cancer Inst. 54:209-217. 
.    Sarma P.S., T. Log. 1973. Subgroup classification of feline leukemia and  
mia  
        virus on early erythroid precursors. Nature 296:156-158. 
8.    Jarrett I, M.C. Goldner, S. Toth, et al. 1984. Interaction between feline     
        leukemia virus Subgroups in the pathogenesis of erythroid hypoplasia. Int. J. 
        Cancer. 34:283-288. 
9.    Russell, P.H., O. Jarrett. 1978. The occurrence of feline leukemia virus  
       neutralizing antibodies in cats. Int. J. Cancer. 22:351-357. 
10.  Vedbrat, S.S., S. Rasheed, H. Lutz, et al. 1983. Feline oncornavirus-associated  
        cell membrane antigen: a viral and not a cellularly coded transformation-specific  
3. Maggio L. 1979. Anemia and the cat. Compendium on continuing education.     
1:114-122. 
4.    Hoover, E.A., G.J. Kociba, W.D. Hardy, Jr. et al. 1974. Erythroid hypoplasia      
 in cats inoculated with feline leukem
5.    Mackey L, W. Jarrett, O. Jarrett, et al. 1975. Anemia associated with feline 
 leukemia virus infection in cats. J.
6
       sarcoma viruses by viral interference and neutralization tests. Virology. 54:160- 
       169. 
7.    Onions D, O. Jarrett, N. Testa, et al. 1982. Selective effect of feline leuke
 74 
 
        antigen of cat lymphomas. Virol -461. 
 
     ematical modeling of cell proliferation: stem cell regulation  
.,  
       
f cell proliferation: stem cell regulation in hemopoiesis, Volume I,       
p. Hematol. 
les in the Plasma of cats with leukemia. Science. 158:1049-1050. 
e leukemia viruses. J. 
virus infection. Nature. 289:385-388. 
llular  
ure red cell aplasia. J. 
ogy. 124:445
11.  Wichmann H-E, M. Loeffler. 1985. Biological description of the model              
   assumptions. In Math
        in hemopoiesis, Volume I, Wichmann, H-E., Loeffler, M. eds. CRC Press, Inc
        Baton Rouge, Florida. 31- 53. 
12.  Wichmann, H-E, M. Loeffler. 1985. Structure of the model. In Mathematical   
        modeling o
        Wichmann, H-E.,Loeffler, M. eds. CRC Press, Inc., Baton Rouge, Florida. 55-    
        86. 
13   Boyce, J.T., E. A. Hoover, G. J. Kociba, et al. 1981. Feline leukemia virus- 
       induced erythroid Aplasia: in vitro hemopoietic culture studies. Ex
       9:990-1001. 
14.  Kawakami, T.G., G.H. Theilen, D.L. Dungworth, et al. 1967. “C”-type viral 
       partic
15.  Fischinger, P.J., S. Blevins, S. Normura. 1974. Simple quantitative assay for  
       both xenotropic murine leukemia virus and ecotropic felin
       Virol. 14:177-179. 
16   Rojko, J.L., E.A. Hoover, S.L. Quackenbush, et al. 1982. Reactivation of 
       latent feline leukemia 
17   Abkowitz, J.L., R.L. Ott, J.M. Nakamura, et al. 1985. Feline G-6-PD ce
       mosaicism: application to the study of retrovirus-induced p
       Clin. Invest. 75:133-140. 
 75 
 
 18.  Abkowitz, J.L., S.N. Caitlin, P. Guttorp. 1997. Strategies for hematopoietic 
development of pure redcell hypoplasia induced 
erbaugh, J.L. Abkowitz. 2000. Cloning of the cellular receptor for the 
P.W. Gasper, C.H. Pontzer, E.A. Hoover. 2003. Mathematical 
 invalid  
-26. 
ci. 81:3402-14. 
Robertson, M, eds. Current Biology, Ltd., London, and 
        Garland Publishing, Inc., New York 2:26-2:30. 
stem cell gene therapy: insights from computer simulated studies. Blood 
89;3192-3198. 
19.   Testa, N.G., D. Onions, O. Jarrett. 1983. Hematopoietic colony formation 
(BFU-E, GM-CFC) during the 
in the cat by feline leukemia virus. Leuk. Res. 7:103-116. 
20.   Gasper, PW. 1984. Ph.D. dissertation. Colorado State University, Fort Collins. 
21.  Quigley J.G., C.C. Burns, M.M. Anderson, E.D. Lynch, K.M. Sabo,  
       J. Ov
       feline leukemia virus subgroup c (FeLV-C), a retrovirus that induces red cell  
       aplasia. Blood 95:1093-9 
22.   Ewen, B.S., 
        Modeling of FeLV- induced EA. Submitted. 
23.   Harrison, S.R. 1990. Regression of a model on Real-system output: an
        test of model validity. Agric. Syst. 34:183-190 
24.   Mitchell, P.L. 1997. Misuse of regression for empirical validation of models. 
        Agric. Syst. 54:313
25     Kohn R.A., K.F. Kalscheur, M. Hanigan. 1998. Evaluation of models for 
         balancing the protein requirements of dairy cows. J. Dairy S
26.   Janeway, Jr., C.A., P. Travers, S. Hunt, M. Walport. 1997. The induction 
        measurement and manipulation of the immune response. In: Immunobiology,  
        Austin, P., Lawrence, E., 
 76 
 
 27.   Yuhki, N, G.F. Heidecker, S.J. O’Brien. 1998. Characterization of MHC 
  cDNA clones in the domestic cat: diversity and evolution of class I genes
  Immunol. 142:3
       . J.  
       676-3682. 
       
       
ites in 
. Hasegawa. 1998. Cloning and mapping of cat (Felis 
.  
93. In: Fundamental Immunology, 
acterization and genetic mapping 
ripheral blood hematopoietic 
28.   Winkler, C., A. Schultz, S. Cevario, S.J. O’Brien. 1989. Genetic  
  characterization of FLA, the cat major histocompatibility complex. PNAS 
  86:943-947. 
29.   Menotti-Raymond, M., V.A. David, L.A. Lyons, A.A. Schaffer, J.F. Tomlin, 
        M.K. Hutton, S.J. O’Brien. 1999. A genetic linkage map of microsatell
        the domestic cat (Felis catus). Genomics ;57:9-23 
30    Cho, K-W, H-Y Youn, M. Okuda, H. Satoh, S. Cevario, S.J. O’Brien, T. 
        Watari, H. Tsujimoto, A
        catus) immunoglobulin and T-cell receptor genes. Immunogenetics 47:226-233
31.   Sprent, J. T lymphocytes and the thymus. 19
         Third Edition. Paul, WE, eds. Raven Press, Ltd, New York. 75-104. 
32.   Yuhki, N., S.J. O’Brien. 1988. Molecular char
         of the class I and class II MHC genes of the domestic cat. Immunogenetics     
         27:414-425. 
33.   Kirschstein, R., Skirboll, L. June 2001, posting date. Stem cells: scientific 
        progress and future research directions. Department of Health and Human 
        Services. [Online.] http://stemcells.nih.gov/info/scireport. 
34.   Till, J.E., E.A. McCulloch. 1961. A direct measurement of the radiation  
         sensitivity of normal  mouse bone marrow cells. Radiat. Res. 14:213 
35.    Gee, AP. 1998. Collection and processing of pe
 77 
 
          progenitor cells. In:Blood stem cell transplantation. Reiffers, J, Goldman, JM,  
pletion for the prevention of graft-versus-host 
homas,  
andez, M.P., R. Arrieta, A. Martinez, P. Garcia, V. Jimenez- 
t with severe combined 
P. de 
 
R., D. Majewski. 1996. Treatment of donor mice with an alpha- 
in 
C)-matched and 
stem cells    
e  
         Armitage, JO, eds. Martin Dunitz Ltd., London. 55-68. 
36.    Kernon, N. 1994. T-cell de
         disease. In: Bone marrow transplantation. Forman, SJ, Blume, KG, T
         ED, eds. Blackwell Scientific Publications, Boston, Mass. 124-135. 
37.    Martin-Hern
         Yuste, F. Hernandez-Navarro. 1997. Haploidentical peripheral blood stem 
         cell transplantation with a combination of CD34 selection and T cell depletion  
         as graft-versus-host disease prophylaxis in a patien
         immunodeficiency. Bone Marrow Transplant. 20(7):797-799. 
38.   Rencher, S.D., J.A. Houston, TD Lockey, JL Hurwitz. 1996. Eliminating 
        graft- versus-host potential from T cell immunotherapeutic populations. Bone 
        Marrow Transplant. 18(2):415-420. 
39.   De Vreis-van der Zwann, A., M.A. van der Pol, A.C. Besseling, L.
        Waal, C.J. Boog. 1998. Haematopoietic stem cells can induce specific skin graft 
         acceptance across full MHC barriers. Bone Marrow Transplant. 22(1):91-98. 
40.   Drobyski, W.
        beta T cell receptor monoclonal antibody induces prolonged T-cell    
        nonresponsiveness and effectively prevents lethal graft-versus-host disease 
        murine recipients of major histocompatibility complex (MH
        MHC-mismatched donor marrow grafts. Blood 87:5355-5369. 
41.   Wang, B., N.S..El-Badris, R.A. Good. 1997. Purified hematopoietic 
         without facilitating cells can repopulate fully allogeniec recipients across entir
 78 
 
         major histocompatibility complex transplantation barriers in mice. PNAS  
        94:14632-14636. 
42.   Clark, P.A., N. Pender. 1995. Transplantation of T-lymphocyte depleted 
         marrow with an addback of T-cells. Hematol. Oncol. 13:219-224. 
43.   Broxmeyer, H.E. 1998. Cord blood stem cell transplantations. In: Blood stem 
W. Holzgreve. 
  
topoietic stem 
         cell transplantations, Reiffers, J., Goldman, JM, Armitage, JO, eds. Martin 
         Duntz, Ltd., London. 233-45. 
44.   Chao, N.J. 1999. Etiology of Graft-versus-Host Disease. In: Graft-versus-Host  
         Disease, NJ Chao, ed., R.G. Landes, Co., Austin Texas. 1999;15-29. 
45.   Surbek, D.V., C. Steinmann, M. Burk, S. Hahn, A. Tichelli, 
        2000. Developmental changes in adhesion molecule expressions in umbilical
        cord blood CD34+  hematopoietic progenitor and stem cells. Am. J. Obstet.  
        Gynecol. 183:1152-57. 
46.   Kincade, P.W., J.M. Gimble. 1993. B lymphocytes. In: Fundamental 
         immunology, Paul, W.E. ed. Raven Press, Ltd., New York. 44-66. 
47.   Gearges, G.E., B.M. Sandmaier, R. Storb. 1998. Animal models. In: Blood 
         stem cell transplantation, Reiffers, J., Goldman, J.M., Armitage, J.O., eds.  
         Martin Dunitz, Ltd., London, 1-17. 
48    Berenson, R.J., R.G. Andrews, W.I. Bensinger. 1988. Antigen CD34+ 
        marrow cells engraft lethally irradiated baboons. J. Clin. Invest. 81:951-955. 
49    Spangrude, G.J. 1994. Biological and clinical aspects of hema
         cells. Annu. Rev. Med. 45:93-104. 
 79 
 
 50.   Andrews, P., P. Anversa, N. Benvenisty, C. Bjornson, H. Blau, D. Bodine, et 
endix E: Markers: how do researchers use them to identify 
-11o, 
atol. 20:1309-1315. 
ood 
t, R.E. Briddell. 1991. Human CD34(+) HLA DR(-) 
ltilineage 
:287-295. 
,  
01.   
topoietic stem and progenitor cells defined 
 
owa, NJ. 1-18. 
57.   Mergia, A., Heinkelein, M.  Foamy Virus Vectors. Curr. Top. Microbiol. 
al. June 2001. App
stem cells. Stem cells: scientific progress and future research directions, 
Department of Health and Human Services. [Online.] 
http://www.nih.gov/news/stemcell/scireport.htm 
51    Li, C.L., G.R. Johnson. 1992. Long-term hemopoietic repopulation by Thy
        Lin-, Ly6A/E+ cells. Exp. Hem
52    Lyman, S.D., S.E.W. Jacobsen. 1998. c-Kit ligand and flt-3 ligand: 
        stem/progenitor cell factors with overlapping yet distinct activities. Bl
        91:1101-1134. 
53.   Kraus, D.S., M.J. Fackler, C.I. Civin, W. May Stratford. 1996. CD34: 
        structure, biology, and clinical utility. Blood 87:1-13. 
54.   Srour, E.F., J.E. Brand
         bone marrow cells contain progenitor cells capable of self-renewal, mu
        differentiation, and long-term in vitro hematopoiesis. Blood Cells 17
55.   Ma, F., M. Wada, H. Yoshino, Y. Ebihara, T. Ishii, A. Manabe, R. Tanaka
        T. Maekawa, M. Ito, H. Mugishima, S. Asano, T. Nakahata, K. Tsuji. 20
        Development of human lymphohema
         by expression of CD34 and CD81. Blood 97:3755-3762. 
56.   Munker, R., E. Hiller, R. Paquette. 2001. Basic biology of hemopoiesis. In:
        Modern hematology: biology and clinical management. Munker, R, Hiller, E,  
        Paquette, R. eds. Humana Press, Tot
 80 
 
         Immunol. In press. 
Ackley, C.D., J.K. Yamamoto, N. Levy, N.C. Pedersen, M.D. Cooper. 1990
 Immunological abnormalities in pathogen free cats experimentally infecte
 feline immunodeficiency virus. J. Virol. 62:5652-5655
Davidson, M.G., J. Rottman, R.V. English, M.R
58.   . 
       d with 
       . 
59.   . Lapin, M.B. Tompkins. 
ppression: 
5-380. 
 of a 
unodeficiency-like 
. 
one marrow transplantation 
        1993. Feline immunodeficiency virus predisposes cats to acute generalized  
        toxoplasmosis. Am. J. Pathol. 143:1486-1497. 
60.   McCheney, M.B., M.B.A. Oldstone. 1989. Virus induced immunosu
        infection with measles virus and human immunodeficiency virus. Adv. 
        Immunol. 45:33
61,   Pedersen, N.C., E.W. Ho, M.L. Brown, J.K. Yamamoto. 1987. Isolation
        T-lymphotropic virus from domestic cats with an imm
        syndrome. Science. 235:790-793.    
62.   Pedersen, N.C., J.K. Yamamotot, T. Ishida, H. Hanson. 1989. Feline 
        immunodeficiency virus infection. Vet. Immunol. Immunopathol. 21:111-129. 
63.   Colgan, S.P., M.A. Thrall, P.W. Gasper, B.J..Rose, R. Fulton, A-M.B 
        Blancquaert, W.J. Bruyninckx. 1991. Restoration of neutrophil and platelet 
        function in feline Chediak-Higashi syndrome of bone marrow transplantation. 
        Bone Marrow  Transplantation 7:365-374. 
64.   Dial, S.M., T. Byrne, M. Haskins, P.W. Gasper, B. Rose, D.A. Wenger, M.A
        Thrall. 1997. Urine glycosaminoglycan concentrations in      
         mucopolysaccharidosis VI-affected cats following b
         or leukocyte infusion. Clinica. Chimica. Acta. 263:1-14. 
 81 
 
 65    Gasper, P.W., D.K. Rosen, R. Fulton. 1996. Allogeneic marrow 
t, M.A. Thrall. 1995. 
 
ilen. 1990. Clinical and 
s, R. Pu, B.L. Homer, F.J. Bova, J.K. Yamamoto. 
ation 
into lethally irradiated recipients. 
 
ved fetal liver cells from DLA-  
f feline 
anine model for gene 
        transplantation for a cat with acute mylogenous leukemia. J. Am. Vet. Med.  
        Assoc. 208:1280-1284. 
66.   Norrdin, R.W., S.J. Simske, S. Gaarde, J.D. Schward
        Bone changes in mucopolysacchardosis VI in cats and the effects of bone  
        marrow transplantation: mechanical testing of long bones. Bone 17:485-489.
67.   Cain, J.L., G.R. Cain, J.M. Turrel, G.H. The
        lymphohematologic responses after bone marrow transplantation in sibling and  
        unrelated donor-recipient pairs of cats. Am. J. Vet. Res. 51:839-844. 
68.   Gengozian, N., L. Reye
        1997. Fractination of feline bone marrow with the soybean agglutinin lectin  
        yields populations enriched for erythroid and myeloid elements: transplant
        of soybean agglutinin-negative cells 
        Transplantation 64:510-518. 
69.   Haskins, M.E., J.A. Wortman, S. Wilson. 1984. Bone marrow transplantation
        in the cat. Transplantation 37:634-636. 
70.   Prummer, O., A. Raghavachar, C. Werner, W. Calvo, F. Carbonell, I. 
        Steinbach, T.M. Fliedner. 1985. Fetal liver transplantation in the dog. 
        Restoration of hemopoiesis with cryopreser
        identical siblings. Transplantation 39:349-355.   
71.   Shacklett, B.L., P.A. Luciw. 1994. Analysis of the vif gene o
         immunodeficiency virus. Virology 204:860-867. 
72.   Stead, R.B., W.W. Kwok, R. Strob, A.D. Miller. 1988. C
 82 
 
         therapy: inefficient gene expression in dogs reconstituted with autologous 
rew. 1998. Gestation age changes in circulating CD34+  
.  
ls  
d 
  
 1996. 
+ hematopoietic progenitor cells by a retroviral 
duced in long-term culture. J. Virol. 
avec, S.  
  
atopoietic stem-progenitor  
07-4716. 
iewicz, R.P. Johnson. 1997. 
        marrow infected with retroviral vectors. Blood 71:742-747. 
73.   Shields, L.E., R.G. And
        hematopoietic stem/progenitor cells in fetal cord blood. Am. J. Obstet. Gynecol
        178:931-937. 
74.   Lim, F., J. Beckloven, A. Brand, J. Kluin-Nelemans, J. Hermans, R. 
        Willemze, H. Kanai, J. Fallenburg. 1999. The number of nucleated cel
        reflects the hematopoietic content of umbilical cord blood for transplantation.  
        Bone Marrow Transplant. 24:965-970. 
75.   Nieto, Y., E.J. Shpall. 1998. CD34+ blood stem cell transplantation. In: Bloo
        stem cell transplantation. Reiffers, J, Goldman, JM, Armitage, JO, eds. Martin
        Dunitz, Ltd., London. 187-196. 
76.   Bahner, L., K. Kearns, Q.L. Hao, E.M. Smogorzewska, D.B. Kohn.
        Transduction of human CD34
        vector expressing an RRE decoy inhibits human immunodeficiency virus type I 
        replication in myelomonocytic cells pro
        70:4352-4360. 
77.   Bonyhadi, M.L., K. Moss, A. Voytovich, J. Auten, C. Kalfoglou, I. Pl
        Forestell, L. Su, E. Bohnlein, H. Kaneshima. 1997. RevM10-expressing T
        cells derived in vivo from transduced human hem
        cells inhibit human immunodeficiency virus replication. J. Virol. 71:47
78.   Rosenzweig, M., D.F. Marks, D. Hempel, J. Lisz
        Transduction of cd34+ hematopoietic progenitor cells with an anti-tat gene 
 83 
 
         protects T-cell and macrophage progeny from AIDS virus infection. J. Virol. 
ncy syndrome: efficient transduction and expression of RevM10 
n of 
te graft-versus-host disease. Blood  
atopoietic stem cells in a large animal. PNAS  
, 
ted  
 marrow. Blood 78:237-245. 
 
        71:2740-2746. 
79.   Su, L., R. Lee, M. Bonyhadi, H. Matsuzaki, S. Forestell, S. Escaich, E. 
        Bohnlein. 1997. Hematopoietic stem cell-based gene therapy for acquired  
        immunodeficie
        in myeloid cells in vivo and in vitro. Blood 89:2283-2290. 
80.   Wagner, J.E., J. Rosenthal, R. Sweetman. 1996. Successful transplantatio
         HLA-matched and HLA-mismatched umbilical cord blood from unrelated 
         donors: analysis of engraftment and acu
         88:795-802. 
81.   Abkowitz, J.L., M.T. Persik, G.H. Shelton, R.L. Ott, S.N. Caitlin, P. 
        Guttorp. 1995. Behavior of hem
        92:2031-2035. 
82.   Lothrop, C.D., Z.S. Al-Lebban, G.P. Niemeyer, J.B. Jones, M.G. Peterson
        J.R. Smith, H.J. Baker, R.C. Morgan, M.A. Eglitis, W.F. Anderson. 1991.  
        Expression of a foreign gene in cats reconstituted with retroviral vectors infec
        autologous bone
83.   Johnson, C.M., D.W. Selleseth, M.N. Ellis, T.A. Childers, M.B. Tompkins.  
        1994. Feline lymphoid tissues engrafted into scid mice maintain morphologic 
         structure and produce feline immunoglobulin. Lab. Anim. Sci. 44:313-318. 
84.   Baum, C.M., L.L. Weissman, A.S. Tsukamoto, A.M. Buckle, B. Peault. 
        1992. Isolation of a candidate human stem-cell population. PNAS 89:2804-2808.
85.   Humeau, L., C. Chabannon, M.T. Firpo, P. Mannoni, C. Bagnis, M.G.  
 84 
 
         Roncarolo, R. Namikawa. 1997. Successful reconstitution of human  
        hematopoiesis in the SCID-hu mouse by genetically modified, highly enriched  
 
 Exp. Hematol.  
e  
S  
06. 
lation 
r 
ow counterparts. Blood 87:3500-3507. 
patic stem cells: potential use for 
onal 
        progenitors isolated from fetal liver. Blood 90:3496-3506. 
86.   Jordan, C.T., C.M. Astle, J. Zawadzki, K. Mackarehtschian, I.R. 
        Lemischka, D.E. Harrison. 1995. Long-term repopulating abilities of enriched 
        fetal liver stem cells measured by competitive repopulation.
        23:1011-1015. 
87.   Morrison, S.J., H.D. Hemmati, A.M. Wandycz, I.L. Weissman. 1995. Th
        purification and characterization of fetal liver hematopoietic stem cells. PNA
        92:10302-103
88.   Rebel, V.I., C.L. Miller, C.J. Eaves, P.M. Lansdorp. 1996. The repopu
        potential of fetal liver hematopoietic stem cells in mice exceeds that of their live
        adult bone marr
89.   Gasper, P.W. 2000. The hematopoietic system. In: The fifth edition of Schalm’s  
        veterinary hematology. Feldman, B.F., Zinkl, J.G., Jain, N.C., eds. Lippincott, 
        Williams & Wilkins, Philadelphia, PA. 
90.   Feldman, G. 2001. Liver transplantation of he
        treating liver diseases. Cell Biol. Toxicol. 17:77-85. 
91.   Zanjani, E.D., J.L. Ascensao, M. Tavassoli. 1992. Homing of liver-derived 
        hemopoietic stem cells to fetal bone marrow. Trans. Am. Phys. 105:7-14. 
92.   Suzuki, A., Y.W. Zheng, K. Fukao, H. Nakauchi, H. Taniguchi. 2001. Cl
        expansion of hepatic stem/progenitor cells following flow cytometric cell 
        sorting. Cell Transplant. 10:393-396. 
 85 
 
 93    Park, J., P.E. Nadeau, A. Mergia. 2002. A Minimal Genome Simian Foamy 
02. 
al.  1996. Vaccination with fixed feline immunodeficiency virus 
 
Stem cell transplantation. In: Cancer principles and practice 
 
ophylaxis of graft- 
e management of graft versus host  
 marrow transplantation in  
 
el for 
s in Breast Cancer, (A.P.M. Forrest and P.  
       Virus  Type 1 (SFV-1) Vector System with Efficient Gene Transfer. Virology.  
       302:236-244. 
94.   Zucali, J. R., T. Ciccarone, V. Kelley, C.M. Johnson, A. Mergia. 20
        Transduction of Umbilical Cord Blood CD 34+ NOD/SCID Repopulating Cells  
        by Simian Foamy Virus Type 1 (SFV-1) Vector. Virology. 302:229-335. 
95.   Bishop, S.A. et 
        (FIV) infected cells: protection, breakthrough and specificity of response.         
        Vaccine 14:1243-50. 
96    Smith, BR. 1997. 
        of oncology, 5th ed. DeVita Jr., VT, Hellman, S, Rosenberg, SA, eds. Lippincot-
        Raven, Philadelphia, PA. 2621-39. 
97.   Lee, J.W., H.J. Deeg. 1997. Choosing a regimen for pr
        versus-host disease. BioDrugs. 7:15-22. 
98.   Plosker, G.L., L.B. Barradell. 1996. Cyclosporin: a review of its 
       pharmacological properties and role in th
       disease. Clin. Immunother. 5:59-90 
99.   Barrett, J. 1992. Graft-versus-host disease. In: Bone
        practice, Barrett, J, Treleaven, J, eds. Churchill Livingstone, London. 257-72. 
100. Zecca, M, F. Locatelli. 2000. Management of graft-versus-host disease in
        paediatric bone marrow transplant recipients. Paediatr. Drugs. 2:29-55. 
101.  Bross I., L. Blumenson, N. Slack, R. Priare. 1968. A Two-Disease Mod
         Breast Cancer. In: Prognostic Factor
 86 
 
          B. Kunkler, eds.) E.& S. Livingstone, Edinburgh, Scotland. 
102.  Tsuji K., M.A. Feng, D. Wang. 2 December 2002. Development of human  
 defined by CD34 and CD81 expression. Leuk 
  
 
 
         lymphohematopoiesis
         Lymphoma. 43(12):2269-73. 
103.  Ma, F., M. Wada, H. Yoshino, Y. Ebihara, T. Ishii, A. Manabe, R. Tanaka, 
         T. Maekawa, M. Ito, H. Mugishima, S. Asano, T. Nakahata, K. Tsuji.
         15 June 2001. Development of human lymphohematopoietic stem and  
         progenitor cells defined by expression of CD34 and CD81. Blood. 97(12):3755-
         3762 
 
 
 
 
 
 
 
 87 
 
